| Oct 11, 2025 | Final Order | |
| Oct 11, 2025 | Action.Phasechange | - |
| Oct 11, 2025 | Action.Issuedecision | - |
| Oct 10, 2025 | Signature Image | - |
| Oct 10, 2025 | Receipt | - |
| Oct 10, 2025 | Other Document | - |
| Oct 10, 2025 | Cover Sheet | - |
| Oct 10, 2025 | Application | - |
| Oct 8, 2025 | Receipt | - |
| Oct 8, 2025 | Further Pleadings | - |
| Oct 8, 2025 | Exhibit | - |
| Oct 8, 2025 | Cover Sheet | - |
| Sep 15, 2025 | Oral Hearing Reference Ic | - |
| Sep 10, 2025 | Written Procedure Closure | - |
| Sep 10, 2025 | Interim Conference Decision | - |
| Sep 10, 2025 | Fix Interim Conference Date | - |
| Aug 8, 2025 | Rejoinder | - |
| Aug 8, 2025 | Exhibit No. B.22 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. 0 | - |
| Aug 8, 2025 | Acknowledgement Of Lodging | - |
| Jul 16, 2025 | Outcome Of The Order | - |
| Jul 16, 2025 | 262 A Final (Again For The Old) | |
| Jul 16, 2025 | 262 A Final | |
| Jul 11, 2025 | Acknowledgement Of Change Of A Representative | - |
| Jul 9, 2025 | Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version | - |
| Jul 9, 2025 | Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February | - |
| Jul 9, 2025 | Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January | - |
| Jul 9, 2025 | Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January | - |
| Jul 9, 2025 | Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January | - |
| Jul 9, 2025 | Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January | - |
| Jul 9, 2025 | Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December | - |
| Jul 9, 2025 | Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November | - |
| Jul 9, 2025 | Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October | - |
| Jul 9, 2025 | Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April | - |
| Jul 9, 2025 | Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives | - |
| Jul 9, 2025 | Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February . | - |
| Jul 9, 2025 | Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November | - |
| Jul 9, 2025 | Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October | - |
| Jul 9, 2025 | Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July | - |
| Jul 9, 2025 | Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June | - |
| Jul 9, 2025 | Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published | - |
| Jul 9, 2025 | Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed) | - |
| Jul 9, 2025 | Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period | - |
| Jul 9, 2025 | Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416 | - |
| Jul 9, 2025 | Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version) | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202 | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July . | - |
| Jul 9, 2025 | Act 16112 And Accord Application 262A Rop 8 July | - |
| Jul 9, 2025 | Acknowledgement Of Lodging | - |
| Jul 8, 2025 | Formal Checks Notification Of Positive Outcome | - |
| Jul 8, 2025 | Application Rop293 Receipt | - |
| Jun 27, 2025 | Application Rop293 | - |
| Jun 27, 2025 | Application | - |
| May 23, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 22, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 22, 2025 | Application Rop293 Receipt | - |
| May 22, 2025 | Application Rop293 | - |
| May 22, 2025 | Application Change Of Representative Jules Fabre Signed | - |
| May 22, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 21, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 21, 2025 | Application Rop293 Receipt | - |
| May 19, 2025 | Application Rop293 | - |
| May 19, 2025 | Application Change Of Representative | - |
| Jan 24, 2025 | Scheduling Ic And Oh For Cc | |
| Jan 24, 2025 | Hearing Dates | - |
| Jan 17, 2025 | R 305 Second Final | |
| Jan 17, 2025 | Outcome Of The Order | - |
| Jan 16, 2025 | Hearing Reference | - |
| Jan 13, 2025 | R 305 Second Oral Comments | - |
| Jan 13, 2025 | Hearing Dates | - |
| Jan 9, 2025 | Receipt | - |
| Jan 9, 2025 | Exhibit No. A.02 | - |
| Jan 9, 2025 | Application | - |
| Dec 19, 2024 | Outcome Of The Order | - |
| Dec 19, 2024 | Extension Request | |
| Dec 10, 2024 | Receipt | - |
| Dec 9, 2024 | 12 09 Accord Request For Extension Of Deadline | - |
| Dec 5, 2024 | Acknowledgement Of Lodging | - |
| Dec 5, 2024 | 12 05 Application To Change Details Of A Representative 64597 | - |
| Nov 1, 2024 | Reply And Defence | - |
| Nov 1, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Nov 1, 2024 | Acknowledgement Of Lodging | - |
| Sep 17, 2024 | Epouploaddocumentsworkflow | - |
| Sep 16, 2024 | Document From Epo | - |
| Sep 6, 2024 | Panel Appointment | - |
| Sep 6, 2024 | Notification Of Service | - |
| Sep 6, 2024 | Epo Request For Case Pending | - |
| Sep 6, 2024 | Acknowledgement Of Lodging | - |
| Sep 6, 2024 | Acknowledgement Of Access To Case | - |
| Sep 4, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Aug 30, 2024 | Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec | - |
| Aug 30, 2024 | Exhibit Pm 6.2 Order 7 June First Instance Court | - |
| Aug 30, 2024 | Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July | - |
| Aug 30, 2024 | Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998 | - |
| Aug 30, 2024 | Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun. | - |
| Aug 30, 2024 | Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere | - |
| Aug 30, 2024 | Exhibit Pm 5.5 Us 065138 A1 | - |
| Aug 30, 2024 | Exhibit Pm 5.4 Declaration By Prof. Stefan Muller | - |
| Aug 30, 2024 | Exhibit Pm 5.3 Declaration By Dr. Kurt Miller | - |
| Aug 30, 2024 | Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us | - |
| Aug 30, 2024 | Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.33 Extracts From Sanofi Annual Report | - |
| Aug 30, 2024 | Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June | - |
| Aug 30, 2024 | Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging | - |
| Aug 30, 2024 | Exhibit Pm 5.30 Screenshot From Openpaymentsdata. | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1) | - |
| Aug 30, 2024 | Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings | - |
| Aug 30, 2024 | Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April | - |
| Aug 30, 2024 | Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December | - |
| Aug 30, 2024 | Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono | - |
| Aug 30, 2024 | Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet | - |
| Aug 30, 2024 | Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May | - |
| Aug 30, 2024 | Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And | - |
| Aug 30, 2024 | Exhibit Pm 5.22 Sanofi Press Release DATED 21 December | - |
| Aug 30, 2024 | Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade | - |
| Aug 30, 2024 | Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study | - |
| Aug 30, 2024 | Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May | - |
| Aug 30, 2024 | Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda | - |
| Aug 30, 2024 | Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October | - |
| Aug 30, 2024 | Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics | - |
| Aug 30, 2024 | Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December | - |
| Aug 30, 2024 | Exhibit Pm 4.9 Further Observations Accord Of 10 December | - |
| Aug 30, 2024 | Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March | - |
| Aug 30, 2024 | Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo | - |
| Aug 30, 2024 | Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation | - |
| Aug 30, 2024 | Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August | - |
| Aug 30, 2024 | Exhibit Pm 4.4 Priority Document No. US61293903(P2) | - |
| Aug 30, 2024 | Exhibit Pm 4.3 Priority Document No. US61256160(P1) | - |
| Aug 30, 2024 | Exhibit Pm 4.2 Wo 051894 A1 | - |
| Aug 30, 2024 | Exhibit Pm 4.1 Ep E 493 466 B1 | - |
| Aug 30, 2024 | Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas | - |
| Aug 30, 2024 | Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October | - |
| Aug 30, 2024 | Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May | - |
| Aug 30, 2024 | Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January | - |
| Aug 30, 2024 | Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January | - |
| Aug 30, 2024 | Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord | - |
| Aug 30, 2024 | Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data) | - |
| Aug 30, 2024 | Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October | - |
| Aug 30, 2024 | Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October | - |
| Aug 30, 2024 | Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February | - |
| Aug 30, 2024 | Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January | - |
| Aug 30, 2024 | Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October | - |
| Aug 30, 2024 | Exhibit Pm 2.2 Neutropenia Msd Manual | - |
| Aug 30, 2024 | Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana | - |
| Aug 30, 2024 | Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July | - |
| Aug 30, 2024 | Exhibit Pm 1.2 Extract Sanofi Annual Reports | - |
| Aug 30, 2024 | Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip | - |
| Aug 30, 2024 | Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August | - |
| Aug 30, 2024 | 44999 Proof Of Court Fees Payment | - |
| Oct 11, 2025 | Final Order | |
| Oct 11, 2025 | Action.Phasechange | - |
| Oct 11, 2025 | Action.Issuedecision | - |
| Oct 10, 2025 | Signature Image | - |
| Oct 10, 2025 | Receipt | - |
| Oct 10, 2025 | Other Document | - |
| Oct 10, 2025 | Cover Sheet | - |
| Oct 10, 2025 | Application | - |
| Oct 8, 2025 | Receipt | - |
| Oct 8, 2025 | Further Pleadings | - |
| Oct 8, 2025 | Exhibit | - |
| Oct 8, 2025 | Cover Sheet | - |
| Sep 15, 2025 | Oral Hearing Reference Ic | - |
| Sep 10, 2025 | Written Procedure Closure | - |
| Sep 10, 2025 | Interim Conference Decision | - |
| Sep 10, 2025 | Fix Interim Conference Date | - |
| Aug 8, 2025 | Rejoinder | - |
| Aug 8, 2025 | Exhibit No. B.22 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. 0 | - |
| Aug 8, 2025 | Acknowledgement Of Lodging | - |
| Jul 16, 2025 | Outcome Of The Order | - |
| Jul 16, 2025 | 262 A Final (Again For The Old) | |
| Jul 16, 2025 | 262 A Final | |
| Jul 11, 2025 | Acknowledgement Of Change Of A Representative | - |
| Jul 9, 2025 | Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version | - |
| Jul 9, 2025 | Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February | - |
| Jul 9, 2025 | Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January | - |
| Jul 9, 2025 | Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January | - |
| Jul 9, 2025 | Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January | - |
| Jul 9, 2025 | Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January | - |
| Jul 9, 2025 | Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December | - |
| Jul 9, 2025 | Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November | - |
| Jul 9, 2025 | Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October | - |
| Jul 9, 2025 | Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April | - |
| Jul 9, 2025 | Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives | - |
| Jul 9, 2025 | Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February . | - |
| Jul 9, 2025 | Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November | - |
| Jul 9, 2025 | Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October | - |
| Jul 9, 2025 | Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July | - |
| Jul 9, 2025 | Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June | - |
| Jul 9, 2025 | Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published | - |
| Jul 9, 2025 | Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed) | - |
| Jul 9, 2025 | Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period | - |
| Jul 9, 2025 | Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416 | - |
| Jul 9, 2025 | Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version) | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202 | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July . | - |
| Jul 9, 2025 | Act 16112 And Accord Application 262A Rop 8 July | - |
| Jul 9, 2025 | Acknowledgement Of Lodging | - |
| Jul 8, 2025 | Formal Checks Notification Of Positive Outcome | - |
| Jul 8, 2025 | Application Rop293 Receipt | - |
| Jun 27, 2025 | Application Rop293 | - |
| Jun 27, 2025 | Application | - |
| May 23, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 22, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 22, 2025 | Application Rop293 Receipt | - |
| May 22, 2025 | Application Rop293 | - |
| May 22, 2025 | Application Change Of Representative Jules Fabre Signed | - |
| May 22, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 21, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 21, 2025 | Application Rop293 Receipt | - |
| May 19, 2025 | Application Rop293 | - |
| May 19, 2025 | Application Change Of Representative | - |
| Jan 24, 2025 | Scheduling Ic And Oh For Cc | |
| Jan 24, 2025 | Hearing Dates | - |
| Jan 17, 2025 | R 305 Second Final | |
| Jan 17, 2025 | Outcome Of The Order | - |
| Jan 16, 2025 | Hearing Reference | - |
| Jan 13, 2025 | R 305 Second Oral Comments | - |
| Jan 13, 2025 | Hearing Dates | - |
| Jan 9, 2025 | Receipt | - |
| Jan 9, 2025 | Exhibit No. A.02 | - |
| Jan 9, 2025 | Application | - |
| Dec 19, 2024 | Outcome Of The Order | - |
| Dec 19, 2024 | Extension Request | |
| Dec 10, 2024 | Receipt | - |
| Dec 9, 2024 | 12 09 Accord Request For Extension Of Deadline | - |
| Dec 5, 2024 | Acknowledgement Of Lodging | - |
| Dec 5, 2024 | 12 05 Application To Change Details Of A Representative 64597 | - |
| Nov 1, 2024 | Reply And Defence | - |
| Nov 1, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Nov 1, 2024 | Acknowledgement Of Lodging | - |
| Sep 17, 2024 | Epouploaddocumentsworkflow | - |
| Sep 16, 2024 | Document From Epo | - |
| Sep 6, 2024 | Panel Appointment | - |
| Sep 6, 2024 | Notification Of Service | - |
| Sep 6, 2024 | Epo Request For Case Pending | - |
| Sep 6, 2024 | Acknowledgement Of Lodging | - |
| Sep 6, 2024 | Acknowledgement Of Access To Case | - |
| Sep 4, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Aug 30, 2024 | Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec | - |
| Aug 30, 2024 | Exhibit Pm 6.2 Order 7 June First Instance Court | - |
| Aug 30, 2024 | Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July | - |
| Aug 30, 2024 | Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998 | - |
| Aug 30, 2024 | Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun. | - |
| Aug 30, 2024 | Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere | - |
| Aug 30, 2024 | Exhibit Pm 5.5 Us 065138 A1 | - |
| Aug 30, 2024 | Exhibit Pm 5.4 Declaration By Prof. Stefan Muller | - |
| Aug 30, 2024 | Exhibit Pm 5.3 Declaration By Dr. Kurt Miller | - |
| Aug 30, 2024 | Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us | - |
| Aug 30, 2024 | Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.33 Extracts From Sanofi Annual Report | - |
| Aug 30, 2024 | Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June | - |
| Aug 30, 2024 | Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging | - |
| Aug 30, 2024 | Exhibit Pm 5.30 Screenshot From Openpaymentsdata. | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1) | - |
| Aug 30, 2024 | Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings | - |
| Aug 30, 2024 | Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April | - |
| Aug 30, 2024 | Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December | - |
| Aug 30, 2024 | Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono | - |
| Aug 30, 2024 | Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet | - |
| Aug 30, 2024 | Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May | - |
| Aug 30, 2024 | Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And | - |
| Aug 30, 2024 | Exhibit Pm 5.22 Sanofi Press Release DATED 21 December | - |
| Aug 30, 2024 | Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade | - |
| Aug 30, 2024 | Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study | - |
| Aug 30, 2024 | Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May | - |
| Aug 30, 2024 | Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda | - |
| Aug 30, 2024 | Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October | - |
| Aug 30, 2024 | Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics | - |
| Aug 30, 2024 | Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December | - |
| Aug 30, 2024 | Exhibit Pm 4.9 Further Observations Accord Of 10 December | - |
| Aug 30, 2024 | Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March | - |
| Aug 30, 2024 | Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo | - |
| Aug 30, 2024 | Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation | - |
| Aug 30, 2024 | Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August | - |
| Aug 30, 2024 | Exhibit Pm 4.4 Priority Document No. US61293903(P2) | - |
| Aug 30, 2024 | Exhibit Pm 4.3 Priority Document No. US61256160(P1) | - |
| Aug 30, 2024 | Exhibit Pm 4.2 Wo 051894 A1 | - |
| Aug 30, 2024 | Exhibit Pm 4.1 Ep E 493 466 B1 | - |
| Aug 30, 2024 | Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas | - |
| Aug 30, 2024 | Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October | - |
| Aug 30, 2024 | Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May | - |
| Aug 30, 2024 | Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January | - |
| Aug 30, 2024 | Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January | - |
| Aug 30, 2024 | Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord | - |
| Aug 30, 2024 | Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data) | - |
| Aug 30, 2024 | Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October | - |
| Aug 30, 2024 | Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October | - |
| Aug 30, 2024 | Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February | - |
| Aug 30, 2024 | Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January | - |
| Aug 30, 2024 | Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October | - |
| Aug 30, 2024 | Exhibit Pm 2.2 Neutropenia Msd Manual | - |
| Aug 30, 2024 | Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana | - |
| Aug 30, 2024 | Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July | - |
| Aug 30, 2024 | Exhibit Pm 1.2 Extract Sanofi Annual Reports | - |
| Aug 30, 2024 | Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip | - |
| Aug 30, 2024 | Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August | - |
| Aug 30, 2024 | 44999 Proof Of Court Fees Payment | - |
| Oct 11, 2025 | Final Order | |
| Oct 11, 2025 | Action.Phasechange | - |
| Oct 11, 2025 | Action.Issuedecision | - |
| Oct 10, 2025 | Signature Image | - |
| Oct 10, 2025 | Receipt | - |
| Oct 10, 2025 | Other Document | - |
| Oct 10, 2025 | Cover Sheet | - |
| Oct 10, 2025 | Application | - |
| Oct 8, 2025 | Receipt | - |
| Oct 8, 2025 | Further Pleadings | - |
| Oct 8, 2025 | Exhibit | - |
| Oct 8, 2025 | Cover Sheet | - |
| Sep 15, 2025 | Oral Hearing Reference Ic | - |
| Sep 10, 2025 | Written Procedure Closure | - |
| Sep 10, 2025 | Interim Conference Decision | - |
| Sep 10, 2025 | Fix Interim Conference Date | - |
| Aug 8, 2025 | Rejoinder | - |
| Aug 8, 2025 | Exhibit No. B.22 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. 0 | - |
| Aug 8, 2025 | Acknowledgement Of Lodging | - |
| Jul 16, 2025 | Outcome Of The Order | - |
| Jul 16, 2025 | 262 A Final (Again For The Old) | |
| Jul 16, 2025 | 262 A Final | |
| Jul 11, 2025 | Acknowledgement Of Change Of A Representative | - |
| Jul 9, 2025 | Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version | - |
| Jul 9, 2025 | Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February | - |
| Jul 9, 2025 | Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January | - |
| Jul 9, 2025 | Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January | - |
| Jul 9, 2025 | Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January | - |
| Jul 9, 2025 | Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January | - |
| Jul 9, 2025 | Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December | - |
| Jul 9, 2025 | Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November | - |
| Jul 9, 2025 | Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October | - |
| Jul 9, 2025 | Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April | - |
| Jul 9, 2025 | Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives | - |
| Jul 9, 2025 | Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February . | - |
| Jul 9, 2025 | Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November | - |
| Jul 9, 2025 | Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October | - |
| Jul 9, 2025 | Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July | - |
| Jul 9, 2025 | Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June | - |
| Jul 9, 2025 | Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published | - |
| Jul 9, 2025 | Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed) | - |
| Jul 9, 2025 | Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period | - |
| Jul 9, 2025 | Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416 | - |
| Jul 9, 2025 | Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version) | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202 | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July . | - |
| Jul 9, 2025 | Act 16112 And Accord Application 262A Rop 8 July | - |
| Jul 9, 2025 | Acknowledgement Of Lodging | - |
| Jul 8, 2025 | Formal Checks Notification Of Positive Outcome | - |
| Jul 8, 2025 | Application Rop293 Receipt | - |
| Jun 27, 2025 | Application Rop293 | - |
| Jun 27, 2025 | Application | - |
| May 23, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 22, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 22, 2025 | Application Rop293 Receipt | - |
| May 22, 2025 | Application Rop293 | - |
| May 22, 2025 | Application Change Of Representative Jules Fabre Signed | - |
| May 22, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 21, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 21, 2025 | Application Rop293 Receipt | - |
| May 19, 2025 | Application Rop293 | - |
| May 19, 2025 | Application Change Of Representative | - |
| Jan 24, 2025 | Scheduling Ic And Oh For Cc | |
| Jan 24, 2025 | Hearing Dates | - |
| Jan 17, 2025 | R 305 Second Final | |
| Jan 17, 2025 | Outcome Of The Order | - |
| Jan 16, 2025 | Hearing Reference | - |
| Jan 13, 2025 | R 305 Second Oral Comments | - |
| Jan 13, 2025 | Hearing Dates | - |
| Jan 9, 2025 | Receipt | - |
| Jan 9, 2025 | Exhibit No. A.02 | - |
| Jan 9, 2025 | Application | - |
| Dec 19, 2024 | Outcome Of The Order | - |
| Dec 19, 2024 | Extension Request | |
| Dec 10, 2024 | Receipt | - |
| Dec 9, 2024 | 12 09 Accord Request For Extension Of Deadline | - |
| Dec 5, 2024 | Acknowledgement Of Lodging | - |
| Dec 5, 2024 | 12 05 Application To Change Details Of A Representative 64597 | - |
| Nov 1, 2024 | Reply And Defence | - |
| Nov 1, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Nov 1, 2024 | Acknowledgement Of Lodging | - |
| Sep 17, 2024 | Epouploaddocumentsworkflow | - |
| Sep 16, 2024 | Document From Epo | - |
| Sep 6, 2024 | Panel Appointment | - |
| Sep 6, 2024 | Notification Of Service | - |
| Sep 6, 2024 | Epo Request For Case Pending | - |
| Sep 6, 2024 | Acknowledgement Of Lodging | - |
| Sep 6, 2024 | Acknowledgement Of Access To Case | - |
| Sep 4, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Aug 30, 2024 | Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec | - |
| Aug 30, 2024 | Exhibit Pm 6.2 Order 7 June First Instance Court | - |
| Aug 30, 2024 | Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July | - |
| Aug 30, 2024 | Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998 | - |
| Aug 30, 2024 | Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun. | - |
| Aug 30, 2024 | Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere | - |
| Aug 30, 2024 | Exhibit Pm 5.5 Us 065138 A1 | - |
| Aug 30, 2024 | Exhibit Pm 5.4 Declaration By Prof. Stefan Muller | - |
| Aug 30, 2024 | Exhibit Pm 5.3 Declaration By Dr. Kurt Miller | - |
| Aug 30, 2024 | Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us | - |
| Aug 30, 2024 | Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.33 Extracts From Sanofi Annual Report | - |
| Aug 30, 2024 | Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June | - |
| Aug 30, 2024 | Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging | - |
| Aug 30, 2024 | Exhibit Pm 5.30 Screenshot From Openpaymentsdata. | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1) | - |
| Aug 30, 2024 | Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings | - |
| Aug 30, 2024 | Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April | - |
| Aug 30, 2024 | Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December | - |
| Aug 30, 2024 | Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono | - |
| Aug 30, 2024 | Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet | - |
| Aug 30, 2024 | Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May | - |
| Aug 30, 2024 | Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And | - |
| Aug 30, 2024 | Exhibit Pm 5.22 Sanofi Press Release DATED 21 December | - |
| Aug 30, 2024 | Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade | - |
| Aug 30, 2024 | Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study | - |
| Aug 30, 2024 | Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May | - |
| Aug 30, 2024 | Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda | - |
| Aug 30, 2024 | Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October | - |
| Aug 30, 2024 | Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics | - |
| Aug 30, 2024 | Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December | - |
| Aug 30, 2024 | Exhibit Pm 4.9 Further Observations Accord Of 10 December | - |
| Aug 30, 2024 | Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March | - |
| Aug 30, 2024 | Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo | - |
| Aug 30, 2024 | Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation | - |
| Aug 30, 2024 | Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August | - |
| Aug 30, 2024 | Exhibit Pm 4.4 Priority Document No. US61293903(P2) | - |
| Aug 30, 2024 | Exhibit Pm 4.3 Priority Document No. US61256160(P1) | - |
| Aug 30, 2024 | Exhibit Pm 4.2 Wo 051894 A1 | - |
| Aug 30, 2024 | Exhibit Pm 4.1 Ep E 493 466 B1 | - |
| Aug 30, 2024 | Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas | - |
| Aug 30, 2024 | Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October | - |
| Aug 30, 2024 | Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May | - |
| Aug 30, 2024 | Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January | - |
| Aug 30, 2024 | Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January | - |
| Aug 30, 2024 | Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord | - |
| Aug 30, 2024 | Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data) | - |
| Aug 30, 2024 | Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October | - |
| Aug 30, 2024 | Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October | - |
| Aug 30, 2024 | Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February | - |
| Aug 30, 2024 | Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January | - |
| Aug 30, 2024 | Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October | - |
| Aug 30, 2024 | Exhibit Pm 2.2 Neutropenia Msd Manual | - |
| Aug 30, 2024 | Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana | - |
| Aug 30, 2024 | Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July | - |
| Aug 30, 2024 | Exhibit Pm 1.2 Extract Sanofi Annual Reports | - |
| Aug 30, 2024 | Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip | - |
| Aug 30, 2024 | Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August | - |
| Aug 30, 2024 | 44999 Proof Of Court Fees Payment | - |
| Oct 11, 2025 | Final Order | |
| Oct 11, 2025 | Action.Phasechange | - |
| Oct 11, 2025 | Action.Issuedecision | - |
| Oct 10, 2025 | Signature Image | - |
| Oct 10, 2025 | Receipt | - |
| Oct 10, 2025 | Other Document | - |
| Oct 10, 2025 | Cover Sheet | - |
| Oct 10, 2025 | Application | - |
| Oct 8, 2025 | Receipt | - |
| Oct 8, 2025 | Further Pleadings | - |
| Oct 8, 2025 | Exhibit | - |
| Oct 8, 2025 | Cover Sheet | - |
| Sep 15, 2025 | Oral Hearing Reference Ic | - |
| Sep 10, 2025 | Written Procedure Closure | - |
| Sep 10, 2025 | Interim Conference Decision | - |
| Sep 10, 2025 | Fix Interim Conference Date | - |
| Aug 8, 2025 | Rejoinder | - |
| Aug 8, 2025 | Exhibit No. B.22 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. 0 | - |
| Aug 8, 2025 | Acknowledgement Of Lodging | - |
| Jul 16, 2025 | Outcome Of The Order | - |
| Jul 16, 2025 | 262 A Final (Again For The Old) | |
| Jul 16, 2025 | 262 A Final | |
| Jul 11, 2025 | Acknowledgement Of Change Of A Representative | - |
| Jul 9, 2025 | Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version | - |
| Jul 9, 2025 | Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February | - |
| Jul 9, 2025 | Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January | - |
| Jul 9, 2025 | Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January | - |
| Jul 9, 2025 | Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January | - |
| Jul 9, 2025 | Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January | - |
| Jul 9, 2025 | Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December | - |
| Jul 9, 2025 | Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November | - |
| Jul 9, 2025 | Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October | - |
| Jul 9, 2025 | Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April | - |
| Jul 9, 2025 | Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives | - |
| Jul 9, 2025 | Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February . | - |
| Jul 9, 2025 | Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November | - |
| Jul 9, 2025 | Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October | - |
| Jul 9, 2025 | Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July | - |
| Jul 9, 2025 | Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June | - |
| Jul 9, 2025 | Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published | - |
| Jul 9, 2025 | Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed) | - |
| Jul 9, 2025 | Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period | - |
| Jul 9, 2025 | Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416 | - |
| Jul 9, 2025 | Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version) | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202 | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July . | - |
| Jul 9, 2025 | Act 16112 And Accord Application 262A Rop 8 July | - |
| Jul 9, 2025 | Acknowledgement Of Lodging | - |
| Jul 8, 2025 | Formal Checks Notification Of Positive Outcome | - |
| Jul 8, 2025 | Application Rop293 Receipt | - |
| Jun 27, 2025 | Application Rop293 | - |
| Jun 27, 2025 | Application | - |
| May 23, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 22, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 22, 2025 | Application Rop293 Receipt | - |
| May 22, 2025 | Application Rop293 | - |
| May 22, 2025 | Application Change Of Representative Jules Fabre Signed | - |
| May 22, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 21, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 21, 2025 | Application Rop293 Receipt | - |
| May 19, 2025 | Application Rop293 | - |
| May 19, 2025 | Application Change Of Representative | - |
| Jan 24, 2025 | Scheduling Ic And Oh For Cc | |
| Jan 24, 2025 | Hearing Dates | - |
| Jan 17, 2025 | R 305 Second Final | |
| Jan 17, 2025 | Outcome Of The Order | - |
| Jan 16, 2025 | Hearing Reference | - |
| Jan 13, 2025 | R 305 Second Oral Comments | - |
| Jan 13, 2025 | Hearing Dates | - |
| Jan 9, 2025 | Receipt | - |
| Jan 9, 2025 | Exhibit No. A.02 | - |
| Jan 9, 2025 | Application | - |
| Dec 19, 2024 | Outcome Of The Order | - |
| Dec 19, 2024 | Extension Request | |
| Dec 10, 2024 | Receipt | - |
| Dec 9, 2024 | 12 09 Accord Request For Extension Of Deadline | - |
| Dec 5, 2024 | Acknowledgement Of Lodging | - |
| Dec 5, 2024 | 12 05 Application To Change Details Of A Representative 64597 | - |
| Nov 1, 2024 | Reply And Defence | - |
| Nov 1, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Nov 1, 2024 | Acknowledgement Of Lodging | - |
| Sep 17, 2024 | Epouploaddocumentsworkflow | - |
| Sep 16, 2024 | Document From Epo | - |
| Sep 6, 2024 | Panel Appointment | - |
| Sep 6, 2024 | Notification Of Service | - |
| Sep 6, 2024 | Epo Request For Case Pending | - |
| Sep 6, 2024 | Acknowledgement Of Lodging | - |
| Sep 6, 2024 | Acknowledgement Of Access To Case | - |
| Sep 4, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Aug 30, 2024 | Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec | - |
| Aug 30, 2024 | Exhibit Pm 6.2 Order 7 June First Instance Court | - |
| Aug 30, 2024 | Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July | - |
| Aug 30, 2024 | Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998 | - |
| Aug 30, 2024 | Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun. | - |
| Aug 30, 2024 | Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere | - |
| Aug 30, 2024 | Exhibit Pm 5.5 Us 065138 A1 | - |
| Aug 30, 2024 | Exhibit Pm 5.4 Declaration By Prof. Stefan Muller | - |
| Aug 30, 2024 | Exhibit Pm 5.3 Declaration By Dr. Kurt Miller | - |
| Aug 30, 2024 | Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us | - |
| Aug 30, 2024 | Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.33 Extracts From Sanofi Annual Report | - |
| Aug 30, 2024 | Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June | - |
| Aug 30, 2024 | Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging | - |
| Aug 30, 2024 | Exhibit Pm 5.30 Screenshot From Openpaymentsdata. | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1) | - |
| Aug 30, 2024 | Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings | - |
| Aug 30, 2024 | Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April | - |
| Aug 30, 2024 | Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December | - |
| Aug 30, 2024 | Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono | - |
| Aug 30, 2024 | Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet | - |
| Aug 30, 2024 | Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May | - |
| Aug 30, 2024 | Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And | - |
| Aug 30, 2024 | Exhibit Pm 5.22 Sanofi Press Release DATED 21 December | - |
| Aug 30, 2024 | Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade | - |
| Aug 30, 2024 | Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study | - |
| Aug 30, 2024 | Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May | - |
| Aug 30, 2024 | Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda | - |
| Aug 30, 2024 | Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October | - |
| Aug 30, 2024 | Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics | - |
| Aug 30, 2024 | Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December | - |
| Aug 30, 2024 | Exhibit Pm 4.9 Further Observations Accord Of 10 December | - |
| Aug 30, 2024 | Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March | - |
| Aug 30, 2024 | Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo | - |
| Aug 30, 2024 | Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation | - |
| Aug 30, 2024 | Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August | - |
| Aug 30, 2024 | Exhibit Pm 4.4 Priority Document No. US61293903(P2) | - |
| Aug 30, 2024 | Exhibit Pm 4.3 Priority Document No. US61256160(P1) | - |
| Aug 30, 2024 | Exhibit Pm 4.2 Wo 051894 A1 | - |
| Aug 30, 2024 | Exhibit Pm 4.1 Ep E 493 466 B1 | - |
| Aug 30, 2024 | Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas | - |
| Aug 30, 2024 | Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October | - |
| Aug 30, 2024 | Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May | - |
| Aug 30, 2024 | Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January | - |
| Aug 30, 2024 | Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January | - |
| Aug 30, 2024 | Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord | - |
| Aug 30, 2024 | Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data) | - |
| Aug 30, 2024 | Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October | - |
| Aug 30, 2024 | Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October | - |
| Aug 30, 2024 | Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February | - |
| Aug 30, 2024 | Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January | - |
| Aug 30, 2024 | Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October | - |
| Aug 30, 2024 | Exhibit Pm 2.2 Neutropenia Msd Manual | - |
| Aug 30, 2024 | Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana | - |
| Aug 30, 2024 | Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July | - |
| Aug 30, 2024 | Exhibit Pm 1.2 Extract Sanofi Annual Reports | - |
| Aug 30, 2024 | Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip | - |
| Aug 30, 2024 | Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August | - |
| Aug 30, 2024 | 44999 Proof Of Court Fees Payment | - |
| Oct 11, 2025 | Final Order | |
| Oct 11, 2025 | Action.Phasechange | - |
| Oct 11, 2025 | Action.Issuedecision | - |
| Oct 10, 2025 | Signature Image | - |
| Oct 10, 2025 | Receipt | - |
| Oct 10, 2025 | Other Document | - |
| Oct 10, 2025 | Cover Sheet | - |
| Oct 10, 2025 | Application | - |
| Oct 8, 2025 | Receipt | - |
| Oct 8, 2025 | Further Pleadings | - |
| Oct 8, 2025 | Exhibit | - |
| Oct 8, 2025 | Cover Sheet | - |
| Sep 15, 2025 | Oral Hearing Reference Ic | - |
| Sep 10, 2025 | Written Procedure Closure | - |
| Sep 10, 2025 | Interim Conference Decision | - |
| Sep 10, 2025 | Fix Interim Conference Date | - |
| Aug 8, 2025 | Rejoinder | - |
| Aug 8, 2025 | Exhibit No. B.22 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. 0 | - |
| Aug 8, 2025 | Acknowledgement Of Lodging | - |
| Jul 16, 2025 | Outcome Of The Order | - |
| Jul 16, 2025 | 262 A Final (Again For The Old) | |
| Jul 16, 2025 | 262 A Final | |
| Jul 11, 2025 | Acknowledgement Of Change Of A Representative | - |
| Jul 9, 2025 | Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version | - |
| Jul 9, 2025 | Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February | - |
| Jul 9, 2025 | Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January | - |
| Jul 9, 2025 | Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January | - |
| Jul 9, 2025 | Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January | - |
| Jul 9, 2025 | Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January | - |
| Jul 9, 2025 | Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December | - |
| Jul 9, 2025 | Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November | - |
| Jul 9, 2025 | Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October | - |
| Jul 9, 2025 | Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April | - |
| Jul 9, 2025 | Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives | - |
| Jul 9, 2025 | Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February . | - |
| Jul 9, 2025 | Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November | - |
| Jul 9, 2025 | Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October | - |
| Jul 9, 2025 | Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July | - |
| Jul 9, 2025 | Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June | - |
| Jul 9, 2025 | Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published | - |
| Jul 9, 2025 | Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed) | - |
| Jul 9, 2025 | Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period | - |
| Jul 9, 2025 | Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416 | - |
| Jul 9, 2025 | Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version) | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202 | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July . | - |
| Jul 9, 2025 | Act 16112 And Accord Application 262A Rop 8 July | - |
| Jul 9, 2025 | Acknowledgement Of Lodging | - |
| Jul 8, 2025 | Formal Checks Notification Of Positive Outcome | - |
| Jul 8, 2025 | Application Rop293 Receipt | - |
| Jun 27, 2025 | Application Rop293 | - |
| Jun 27, 2025 | Application | - |
| May 23, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 22, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 22, 2025 | Application Rop293 Receipt | - |
| May 22, 2025 | Application Rop293 | - |
| May 22, 2025 | Application Change Of Representative Jules Fabre Signed | - |
| May 22, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 21, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 21, 2025 | Application Rop293 Receipt | - |
| May 19, 2025 | Application Rop293 | - |
| May 19, 2025 | Application Change Of Representative | - |
| Jan 24, 2025 | Scheduling Ic And Oh For Cc | |
| Jan 24, 2025 | Hearing Dates | - |
| Jan 17, 2025 | R 305 Second Final | |
| Jan 17, 2025 | Outcome Of The Order | - |
| Jan 16, 2025 | Hearing Reference | - |
| Jan 13, 2025 | R 305 Second Oral Comments | - |
| Jan 13, 2025 | Hearing Dates | - |
| Jan 9, 2025 | Receipt | - |
| Jan 9, 2025 | Exhibit No. A.02 | - |
| Jan 9, 2025 | Application | - |
| Dec 19, 2024 | Outcome Of The Order | - |
| Dec 19, 2024 | Extension Request | |
| Dec 10, 2024 | Receipt | - |
| Dec 9, 2024 | 12 09 Accord Request For Extension Of Deadline | - |
| Dec 5, 2024 | Acknowledgement Of Lodging | - |
| Dec 5, 2024 | 12 05 Application To Change Details Of A Representative 64597 | - |
| Nov 1, 2024 | Reply And Defence | - |
| Nov 1, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Nov 1, 2024 | Acknowledgement Of Lodging | - |
| Sep 17, 2024 | Epouploaddocumentsworkflow | - |
| Sep 16, 2024 | Document From Epo | - |
| Sep 6, 2024 | Panel Appointment | - |
| Sep 6, 2024 | Notification Of Service | - |
| Sep 6, 2024 | Epo Request For Case Pending | - |
| Sep 6, 2024 | Acknowledgement Of Lodging | - |
| Sep 6, 2024 | Acknowledgement Of Access To Case | - |
| Sep 4, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Aug 30, 2024 | Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec | - |
| Aug 30, 2024 | Exhibit Pm 6.2 Order 7 June First Instance Court | - |
| Aug 30, 2024 | Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July | - |
| Aug 30, 2024 | Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998 | - |
| Aug 30, 2024 | Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun. | - |
| Aug 30, 2024 | Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere | - |
| Aug 30, 2024 | Exhibit Pm 5.5 Us 065138 A1 | - |
| Aug 30, 2024 | Exhibit Pm 5.4 Declaration By Prof. Stefan Muller | - |
| Aug 30, 2024 | Exhibit Pm 5.3 Declaration By Dr. Kurt Miller | - |
| Aug 30, 2024 | Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us | - |
| Aug 30, 2024 | Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.33 Extracts From Sanofi Annual Report | - |
| Aug 30, 2024 | Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June | - |
| Aug 30, 2024 | Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging | - |
| Aug 30, 2024 | Exhibit Pm 5.30 Screenshot From Openpaymentsdata. | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1) | - |
| Aug 30, 2024 | Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings | - |
| Aug 30, 2024 | Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April | - |
| Aug 30, 2024 | Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December | - |
| Aug 30, 2024 | Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono | - |
| Aug 30, 2024 | Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet | - |
| Aug 30, 2024 | Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May | - |
| Aug 30, 2024 | Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And | - |
| Aug 30, 2024 | Exhibit Pm 5.22 Sanofi Press Release DATED 21 December | - |
| Aug 30, 2024 | Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade | - |
| Aug 30, 2024 | Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study | - |
| Aug 30, 2024 | Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May | - |
| Aug 30, 2024 | Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda | - |
| Aug 30, 2024 | Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October | - |
| Aug 30, 2024 | Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics | - |
| Aug 30, 2024 | Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December | - |
| Aug 30, 2024 | Exhibit Pm 4.9 Further Observations Accord Of 10 December | - |
| Aug 30, 2024 | Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March | - |
| Aug 30, 2024 | Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo | - |
| Aug 30, 2024 | Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation | - |
| Aug 30, 2024 | Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August | - |
| Aug 30, 2024 | Exhibit Pm 4.4 Priority Document No. US61293903(P2) | - |
| Aug 30, 2024 | Exhibit Pm 4.3 Priority Document No. US61256160(P1) | - |
| Aug 30, 2024 | Exhibit Pm 4.2 Wo 051894 A1 | - |
| Aug 30, 2024 | Exhibit Pm 4.1 Ep E 493 466 B1 | - |
| Aug 30, 2024 | Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas | - |
| Aug 30, 2024 | Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October | - |
| Aug 30, 2024 | Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May | - |
| Aug 30, 2024 | Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January | - |
| Aug 30, 2024 | Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January | - |
| Aug 30, 2024 | Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord | - |
| Aug 30, 2024 | Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data) | - |
| Aug 30, 2024 | Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October | - |
| Aug 30, 2024 | Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October | - |
| Aug 30, 2024 | Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February | - |
| Aug 30, 2024 | Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January | - |
| Aug 30, 2024 | Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October | - |
| Aug 30, 2024 | Exhibit Pm 2.2 Neutropenia Msd Manual | - |
| Aug 30, 2024 | Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana | - |
| Aug 30, 2024 | Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July | - |
| Aug 30, 2024 | Exhibit Pm 1.2 Extract Sanofi Annual Reports | - |
| Aug 30, 2024 | Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip | - |
| Aug 30, 2024 | Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August | - |
| Aug 30, 2024 | 44999 Proof Of Court Fees Payment | - |
| Oct 11, 2025 | Final Order | |
| Oct 11, 2025 | Action.Phasechange | - |
| Oct 11, 2025 | Action.Issuedecision | - |
| Oct 10, 2025 | Signature Image | - |
| Oct 10, 2025 | Receipt | - |
| Oct 10, 2025 | Other Document | - |
| Oct 10, 2025 | Cover Sheet | - |
| Oct 10, 2025 | Application | - |
| Oct 8, 2025 | Receipt | - |
| Oct 8, 2025 | Further Pleadings | - |
| Oct 8, 2025 | Exhibit | - |
| Oct 8, 2025 | Cover Sheet | - |
| Sep 15, 2025 | Oral Hearing Reference Ic | - |
| Sep 10, 2025 | Written Procedure Closure | - |
| Sep 10, 2025 | Interim Conference Decision | - |
| Sep 10, 2025 | Fix Interim Conference Date | - |
| Aug 8, 2025 | Rejoinder | - |
| Aug 8, 2025 | Exhibit No. B.22 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. 0 | - |
| Aug 8, 2025 | Acknowledgement Of Lodging | - |
| Jul 16, 2025 | Outcome Of The Order | - |
| Jul 16, 2025 | 262 A Final (Again For The Old) | |
| Jul 16, 2025 | 262 A Final | |
| Jul 11, 2025 | Acknowledgement Of Change Of A Representative | - |
| Jul 9, 2025 | Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version | - |
| Jul 9, 2025 | Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February | - |
| Jul 9, 2025 | Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January | - |
| Jul 9, 2025 | Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January | - |
| Jul 9, 2025 | Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January | - |
| Jul 9, 2025 | Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January | - |
| Jul 9, 2025 | Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December | - |
| Jul 9, 2025 | Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November | - |
| Jul 9, 2025 | Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October | - |
| Jul 9, 2025 | Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April | - |
| Jul 9, 2025 | Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives | - |
| Jul 9, 2025 | Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February . | - |
| Jul 9, 2025 | Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November | - |
| Jul 9, 2025 | Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October | - |
| Jul 9, 2025 | Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July | - |
| Jul 9, 2025 | Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June | - |
| Jul 9, 2025 | Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published | - |
| Jul 9, 2025 | Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed) | - |
| Jul 9, 2025 | Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period | - |
| Jul 9, 2025 | Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416 | - |
| Jul 9, 2025 | Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version) | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202 | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July . | - |
| Jul 9, 2025 | Act 16112 And Accord Application 262A Rop 8 July | - |
| Jul 9, 2025 | Acknowledgement Of Lodging | - |
| Jul 8, 2025 | Formal Checks Notification Of Positive Outcome | - |
| Jul 8, 2025 | Application Rop293 Receipt | - |
| Jun 27, 2025 | Application Rop293 | - |
| Jun 27, 2025 | Application | - |
| May 23, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 22, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 22, 2025 | Application Rop293 Receipt | - |
| May 22, 2025 | Application Rop293 | - |
| May 22, 2025 | Application Change Of Representative Jules Fabre Signed | - |
| May 22, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 21, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 21, 2025 | Application Rop293 Receipt | - |
| May 19, 2025 | Application Rop293 | - |
| May 19, 2025 | Application Change Of Representative | - |
| Jan 24, 2025 | Scheduling Ic And Oh For Cc | |
| Jan 24, 2025 | Hearing Dates | - |
| Jan 17, 2025 | R 305 Second Final | |
| Jan 17, 2025 | Outcome Of The Order | - |
| Jan 16, 2025 | Hearing Reference | - |
| Jan 13, 2025 | R 305 Second Oral Comments | - |
| Jan 13, 2025 | Hearing Dates | - |
| Jan 9, 2025 | Receipt | - |
| Jan 9, 2025 | Exhibit No. A.02 | - |
| Jan 9, 2025 | Application | - |
| Dec 19, 2024 | Outcome Of The Order | - |
| Dec 19, 2024 | Extension Request | |
| Dec 10, 2024 | Receipt | - |
| Dec 9, 2024 | 12 09 Accord Request For Extension Of Deadline | - |
| Dec 5, 2024 | Acknowledgement Of Lodging | - |
| Dec 5, 2024 | 12 05 Application To Change Details Of A Representative 64597 | - |
| Nov 1, 2024 | Reply And Defence | - |
| Nov 1, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Nov 1, 2024 | Acknowledgement Of Lodging | - |
| Sep 17, 2024 | Epouploaddocumentsworkflow | - |
| Sep 16, 2024 | Document From Epo | - |
| Sep 6, 2024 | Panel Appointment | - |
| Sep 6, 2024 | Notification Of Service | - |
| Sep 6, 2024 | Epo Request For Case Pending | - |
| Sep 6, 2024 | Acknowledgement Of Lodging | - |
| Sep 6, 2024 | Acknowledgement Of Access To Case | - |
| Sep 4, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Aug 30, 2024 | Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec | - |
| Aug 30, 2024 | Exhibit Pm 6.2 Order 7 June First Instance Court | - |
| Aug 30, 2024 | Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July | - |
| Aug 30, 2024 | Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998 | - |
| Aug 30, 2024 | Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun. | - |
| Aug 30, 2024 | Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere | - |
| Aug 30, 2024 | Exhibit Pm 5.5 Us 065138 A1 | - |
| Aug 30, 2024 | Exhibit Pm 5.4 Declaration By Prof. Stefan Muller | - |
| Aug 30, 2024 | Exhibit Pm 5.3 Declaration By Dr. Kurt Miller | - |
| Aug 30, 2024 | Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us | - |
| Aug 30, 2024 | Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.33 Extracts From Sanofi Annual Report | - |
| Aug 30, 2024 | Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June | - |
| Aug 30, 2024 | Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging | - |
| Aug 30, 2024 | Exhibit Pm 5.30 Screenshot From Openpaymentsdata. | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1) | - |
| Aug 30, 2024 | Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings | - |
| Aug 30, 2024 | Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April | - |
| Aug 30, 2024 | Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December | - |
| Aug 30, 2024 | Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono | - |
| Aug 30, 2024 | Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet | - |
| Aug 30, 2024 | Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May | - |
| Aug 30, 2024 | Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And | - |
| Aug 30, 2024 | Exhibit Pm 5.22 Sanofi Press Release DATED 21 December | - |
| Aug 30, 2024 | Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade | - |
| Aug 30, 2024 | Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study | - |
| Aug 30, 2024 | Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May | - |
| Aug 30, 2024 | Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda | - |
| Aug 30, 2024 | Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October | - |
| Aug 30, 2024 | Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics | - |
| Aug 30, 2024 | Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December | - |
| Aug 30, 2024 | Exhibit Pm 4.9 Further Observations Accord Of 10 December | - |
| Aug 30, 2024 | Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March | - |
| Aug 30, 2024 | Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo | - |
| Aug 30, 2024 | Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation | - |
| Aug 30, 2024 | Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August | - |
| Aug 30, 2024 | Exhibit Pm 4.4 Priority Document No. US61293903(P2) | - |
| Aug 30, 2024 | Exhibit Pm 4.3 Priority Document No. US61256160(P1) | - |
| Aug 30, 2024 | Exhibit Pm 4.2 Wo 051894 A1 | - |
| Aug 30, 2024 | Exhibit Pm 4.1 Ep E 493 466 B1 | - |
| Aug 30, 2024 | Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas | - |
| Aug 30, 2024 | Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October | - |
| Aug 30, 2024 | Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May | - |
| Aug 30, 2024 | Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January | - |
| Aug 30, 2024 | Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January | - |
| Aug 30, 2024 | Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord | - |
| Aug 30, 2024 | Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data) | - |
| Aug 30, 2024 | Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October | - |
| Aug 30, 2024 | Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October | - |
| Aug 30, 2024 | Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February | - |
| Aug 30, 2024 | Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January | - |
| Aug 30, 2024 | Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October | - |
| Aug 30, 2024 | Exhibit Pm 2.2 Neutropenia Msd Manual | - |
| Aug 30, 2024 | Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana | - |
| Aug 30, 2024 | Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July | - |
| Aug 30, 2024 | Exhibit Pm 1.2 Extract Sanofi Annual Reports | - |
| Aug 30, 2024 | Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip | - |
| Aug 30, 2024 | Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August | - |
| Aug 30, 2024 | 44999 Proof Of Court Fees Payment | - |
| Oct 11, 2025 | Final Order | |
| Oct 11, 2025 | Action.Phasechange | - |
| Oct 11, 2025 | Action.Issuedecision | - |
| Oct 10, 2025 | Signature Image | - |
| Oct 10, 2025 | Receipt | - |
| Oct 10, 2025 | Other Document | - |
| Oct 10, 2025 | Cover Sheet | - |
| Oct 10, 2025 | Application | - |
| Oct 8, 2025 | Receipt | - |
| Oct 8, 2025 | Further Pleadings | - |
| Oct 8, 2025 | Exhibit | - |
| Oct 8, 2025 | Cover Sheet | - |
| Sep 15, 2025 | Oral Hearing Reference Ic | - |
| Sep 10, 2025 | Written Procedure Closure | - |
| Sep 10, 2025 | Interim Conference Decision | - |
| Sep 10, 2025 | Fix Interim Conference Date | - |
| Aug 8, 2025 | Rejoinder | - |
| Aug 8, 2025 | Exhibit No. B.22 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. 0 | - |
| Aug 8, 2025 | Acknowledgement Of Lodging | - |
| Jul 16, 2025 | Outcome Of The Order | - |
| Jul 16, 2025 | 262 A Final (Again For The Old) | |
| Jul 16, 2025 | 262 A Final | |
| Jul 11, 2025 | Acknowledgement Of Change Of A Representative | - |
| Jul 9, 2025 | Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version | - |
| Jul 9, 2025 | Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February | - |
| Jul 9, 2025 | Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January | - |
| Jul 9, 2025 | Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January | - |
| Jul 9, 2025 | Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January | - |
| Jul 9, 2025 | Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January | - |
| Jul 9, 2025 | Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December | - |
| Jul 9, 2025 | Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November | - |
| Jul 9, 2025 | Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October | - |
| Jul 9, 2025 | Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April | - |
| Jul 9, 2025 | Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives | - |
| Jul 9, 2025 | Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February . | - |
| Jul 9, 2025 | Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November | - |
| Jul 9, 2025 | Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October | - |
| Jul 9, 2025 | Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July | - |
| Jul 9, 2025 | Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June | - |
| Jul 9, 2025 | Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published | - |
| Jul 9, 2025 | Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed) | - |
| Jul 9, 2025 | Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period | - |
| Jul 9, 2025 | Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416 | - |
| Jul 9, 2025 | Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version) | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202 | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July . | - |
| Jul 9, 2025 | Act 16112 And Accord Application 262A Rop 8 July | - |
| Jul 9, 2025 | Acknowledgement Of Lodging | - |
| Jul 8, 2025 | Formal Checks Notification Of Positive Outcome | - |
| Jul 8, 2025 | Application Rop293 Receipt | - |
| Jun 27, 2025 | Application Rop293 | - |
| Jun 27, 2025 | Application | - |
| May 23, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 22, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 22, 2025 | Application Rop293 Receipt | - |
| May 22, 2025 | Application Rop293 | - |
| May 22, 2025 | Application Change Of Representative Jules Fabre Signed | - |
| May 22, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 21, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 21, 2025 | Application Rop293 Receipt | - |
| May 19, 2025 | Application Rop293 | - |
| May 19, 2025 | Application Change Of Representative | - |
| Jan 24, 2025 | Scheduling Ic And Oh For Cc | |
| Jan 24, 2025 | Hearing Dates | - |
| Jan 17, 2025 | R 305 Second Final | |
| Jan 17, 2025 | Outcome Of The Order | - |
| Jan 16, 2025 | Hearing Reference | - |
| Jan 13, 2025 | R 305 Second Oral Comments | - |
| Jan 13, 2025 | Hearing Dates | - |
| Jan 9, 2025 | Receipt | - |
| Jan 9, 2025 | Exhibit No. A.02 | - |
| Jan 9, 2025 | Application | - |
| Dec 19, 2024 | Outcome Of The Order | - |
| Dec 19, 2024 | Extension Request | |
| Dec 10, 2024 | Receipt | - |
| Dec 9, 2024 | 12 09 Accord Request For Extension Of Deadline | - |
| Dec 5, 2024 | Acknowledgement Of Lodging | - |
| Dec 5, 2024 | 12 05 Application To Change Details Of A Representative 64597 | - |
| Nov 1, 2024 | Reply And Defence | - |
| Nov 1, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Nov 1, 2024 | Acknowledgement Of Lodging | - |
| Sep 17, 2024 | Epouploaddocumentsworkflow | - |
| Sep 16, 2024 | Document From Epo | - |
| Sep 6, 2024 | Panel Appointment | - |
| Sep 6, 2024 | Notification Of Service | - |
| Sep 6, 2024 | Epo Request For Case Pending | - |
| Sep 6, 2024 | Acknowledgement Of Lodging | - |
| Sep 6, 2024 | Acknowledgement Of Access To Case | - |
| Sep 4, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Aug 30, 2024 | Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec | - |
| Aug 30, 2024 | Exhibit Pm 6.2 Order 7 June First Instance Court | - |
| Aug 30, 2024 | Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July | - |
| Aug 30, 2024 | Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998 | - |
| Aug 30, 2024 | Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun. | - |
| Aug 30, 2024 | Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere | - |
| Aug 30, 2024 | Exhibit Pm 5.5 Us 065138 A1 | - |
| Aug 30, 2024 | Exhibit Pm 5.4 Declaration By Prof. Stefan Muller | - |
| Aug 30, 2024 | Exhibit Pm 5.3 Declaration By Dr. Kurt Miller | - |
| Aug 30, 2024 | Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us | - |
| Aug 30, 2024 | Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.33 Extracts From Sanofi Annual Report | - |
| Aug 30, 2024 | Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June | - |
| Aug 30, 2024 | Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging | - |
| Aug 30, 2024 | Exhibit Pm 5.30 Screenshot From Openpaymentsdata. | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1) | - |
| Aug 30, 2024 | Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings | - |
| Aug 30, 2024 | Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April | - |
| Aug 30, 2024 | Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December | - |
| Aug 30, 2024 | Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono | - |
| Aug 30, 2024 | Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet | - |
| Aug 30, 2024 | Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May | - |
| Aug 30, 2024 | Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And | - |
| Aug 30, 2024 | Exhibit Pm 5.22 Sanofi Press Release DATED 21 December | - |
| Aug 30, 2024 | Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade | - |
| Aug 30, 2024 | Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study | - |
| Aug 30, 2024 | Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May | - |
| Aug 30, 2024 | Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda | - |
| Aug 30, 2024 | Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October | - |
| Aug 30, 2024 | Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics | - |
| Aug 30, 2024 | Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December | - |
| Aug 30, 2024 | Exhibit Pm 4.9 Further Observations Accord Of 10 December | - |
| Aug 30, 2024 | Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March | - |
| Aug 30, 2024 | Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo | - |
| Aug 30, 2024 | Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation | - |
| Aug 30, 2024 | Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August | - |
| Aug 30, 2024 | Exhibit Pm 4.4 Priority Document No. US61293903(P2) | - |
| Aug 30, 2024 | Exhibit Pm 4.3 Priority Document No. US61256160(P1) | - |
| Aug 30, 2024 | Exhibit Pm 4.2 Wo 051894 A1 | - |
| Aug 30, 2024 | Exhibit Pm 4.1 Ep E 493 466 B1 | - |
| Aug 30, 2024 | Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas | - |
| Aug 30, 2024 | Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October | - |
| Aug 30, 2024 | Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May | - |
| Aug 30, 2024 | Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January | - |
| Aug 30, 2024 | Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January | - |
| Aug 30, 2024 | Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord | - |
| Aug 30, 2024 | Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data) | - |
| Aug 30, 2024 | Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October | - |
| Aug 30, 2024 | Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October | - |
| Aug 30, 2024 | Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February | - |
| Aug 30, 2024 | Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January | - |
| Aug 30, 2024 | Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October | - |
| Aug 30, 2024 | Exhibit Pm 2.2 Neutropenia Msd Manual | - |
| Aug 30, 2024 | Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana | - |
| Aug 30, 2024 | Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July | - |
| Aug 30, 2024 | Exhibit Pm 1.2 Extract Sanofi Annual Reports | - |
| Aug 30, 2024 | Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip | - |
| Aug 30, 2024 | Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August | - |
| Aug 30, 2024 | 44999 Proof Of Court Fees Payment | - |
| Oct 11, 2025 | Final Order | |
| Oct 11, 2025 | Action.Phasechange | - |
| Oct 11, 2025 | Action.Issuedecision | - |
| Oct 10, 2025 | Signature Image | - |
| Oct 10, 2025 | Receipt | - |
| Oct 10, 2025 | Other Document | - |
| Oct 10, 2025 | Cover Sheet | - |
| Oct 10, 2025 | Application | - |
| Oct 8, 2025 | Receipt | - |
| Oct 8, 2025 | Further Pleadings | - |
| Oct 8, 2025 | Exhibit | - |
| Oct 8, 2025 | Cover Sheet | - |
| Sep 15, 2025 | Oral Hearing Reference Ic | - |
| Sep 10, 2025 | Written Procedure Closure | - |
| Sep 10, 2025 | Interim Conference Decision | - |
| Sep 10, 2025 | Fix Interim Conference Date | - |
| Aug 8, 2025 | Rejoinder | - |
| Aug 8, 2025 | Exhibit No. B.22 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. 0 | - |
| Aug 8, 2025 | Acknowledgement Of Lodging | - |
| Jul 16, 2025 | Outcome Of The Order | - |
| Jul 16, 2025 | 262 A Final (Again For The Old) | |
| Jul 16, 2025 | 262 A Final | |
| Jul 11, 2025 | Acknowledgement Of Change Of A Representative | - |
| Jul 9, 2025 | Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version | - |
| Jul 9, 2025 | Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February | - |
| Jul 9, 2025 | Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January | - |
| Jul 9, 2025 | Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January | - |
| Jul 9, 2025 | Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January | - |
| Jul 9, 2025 | Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January | - |
| Jul 9, 2025 | Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December | - |
| Jul 9, 2025 | Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November | - |
| Jul 9, 2025 | Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October | - |
| Jul 9, 2025 | Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April | - |
| Jul 9, 2025 | Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives | - |
| Jul 9, 2025 | Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February . | - |
| Jul 9, 2025 | Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November | - |
| Jul 9, 2025 | Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October | - |
| Jul 9, 2025 | Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July | - |
| Jul 9, 2025 | Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June | - |
| Jul 9, 2025 | Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published | - |
| Jul 9, 2025 | Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed) | - |
| Jul 9, 2025 | Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period | - |
| Jul 9, 2025 | Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416 | - |
| Jul 9, 2025 | Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version) | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202 | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July . | - |
| Jul 9, 2025 | Act 16112 And Accord Application 262A Rop 8 July | - |
| Jul 9, 2025 | Acknowledgement Of Lodging | - |
| Jul 8, 2025 | Formal Checks Notification Of Positive Outcome | - |
| Jul 8, 2025 | Application Rop293 Receipt | - |
| Jun 27, 2025 | Application Rop293 | - |
| Jun 27, 2025 | Application | - |
| May 23, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 22, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 22, 2025 | Application Rop293 Receipt | - |
| May 22, 2025 | Application Rop293 | - |
| May 22, 2025 | Application Change Of Representative Jules Fabre Signed | - |
| May 22, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 21, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 21, 2025 | Application Rop293 Receipt | - |
| May 19, 2025 | Application Rop293 | - |
| May 19, 2025 | Application Change Of Representative | - |
| Jan 24, 2025 | Scheduling Ic And Oh For Cc | |
| Jan 24, 2025 | Hearing Dates | - |
| Jan 17, 2025 | R 305 Second Final | |
| Jan 17, 2025 | Outcome Of The Order | - |
| Jan 16, 2025 | Hearing Reference | - |
| Jan 13, 2025 | R 305 Second Oral Comments | - |
| Jan 13, 2025 | Hearing Dates | - |
| Jan 9, 2025 | Receipt | - |
| Jan 9, 2025 | Exhibit No. A.02 | - |
| Jan 9, 2025 | Application | - |
| Dec 19, 2024 | Outcome Of The Order | - |
| Dec 19, 2024 | Extension Request | |
| Dec 10, 2024 | Receipt | - |
| Dec 9, 2024 | 12 09 Accord Request For Extension Of Deadline | - |
| Dec 5, 2024 | Acknowledgement Of Lodging | - |
| Dec 5, 2024 | 12 05 Application To Change Details Of A Representative 64597 | - |
| Nov 1, 2024 | Reply And Defence | - |
| Nov 1, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Nov 1, 2024 | Acknowledgement Of Lodging | - |
| Sep 17, 2024 | Epouploaddocumentsworkflow | - |
| Sep 16, 2024 | Document From Epo | - |
| Sep 6, 2024 | Panel Appointment | - |
| Sep 6, 2024 | Notification Of Service | - |
| Sep 6, 2024 | Epo Request For Case Pending | - |
| Sep 6, 2024 | Acknowledgement Of Lodging | - |
| Sep 6, 2024 | Acknowledgement Of Access To Case | - |
| Sep 4, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Aug 30, 2024 | Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec | - |
| Aug 30, 2024 | Exhibit Pm 6.2 Order 7 June First Instance Court | - |
| Aug 30, 2024 | Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July | - |
| Aug 30, 2024 | Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998 | - |
| Aug 30, 2024 | Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun. | - |
| Aug 30, 2024 | Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere | - |
| Aug 30, 2024 | Exhibit Pm 5.5 Us 065138 A1 | - |
| Aug 30, 2024 | Exhibit Pm 5.4 Declaration By Prof. Stefan Muller | - |
| Aug 30, 2024 | Exhibit Pm 5.3 Declaration By Dr. Kurt Miller | - |
| Aug 30, 2024 | Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us | - |
| Aug 30, 2024 | Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.33 Extracts From Sanofi Annual Report | - |
| Aug 30, 2024 | Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June | - |
| Aug 30, 2024 | Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging | - |
| Aug 30, 2024 | Exhibit Pm 5.30 Screenshot From Openpaymentsdata. | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1) | - |
| Aug 30, 2024 | Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings | - |
| Aug 30, 2024 | Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April | - |
| Aug 30, 2024 | Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December | - |
| Aug 30, 2024 | Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono | - |
| Aug 30, 2024 | Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet | - |
| Aug 30, 2024 | Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May | - |
| Aug 30, 2024 | Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And | - |
| Aug 30, 2024 | Exhibit Pm 5.22 Sanofi Press Release DATED 21 December | - |
| Aug 30, 2024 | Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade | - |
| Aug 30, 2024 | Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study | - |
| Aug 30, 2024 | Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May | - |
| Aug 30, 2024 | Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda | - |
| Aug 30, 2024 | Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October | - |
| Aug 30, 2024 | Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics | - |
| Aug 30, 2024 | Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December | - |
| Aug 30, 2024 | Exhibit Pm 4.9 Further Observations Accord Of 10 December | - |
| Aug 30, 2024 | Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March | - |
| Aug 30, 2024 | Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo | - |
| Aug 30, 2024 | Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation | - |
| Aug 30, 2024 | Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August | - |
| Aug 30, 2024 | Exhibit Pm 4.4 Priority Document No. US61293903(P2) | - |
| Aug 30, 2024 | Exhibit Pm 4.3 Priority Document No. US61256160(P1) | - |
| Aug 30, 2024 | Exhibit Pm 4.2 Wo 051894 A1 | - |
| Aug 30, 2024 | Exhibit Pm 4.1 Ep E 493 466 B1 | - |
| Aug 30, 2024 | Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas | - |
| Aug 30, 2024 | Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October | - |
| Aug 30, 2024 | Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May | - |
| Aug 30, 2024 | Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January | - |
| Aug 30, 2024 | Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January | - |
| Aug 30, 2024 | Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord | - |
| Aug 30, 2024 | Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data) | - |
| Aug 30, 2024 | Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October | - |
| Aug 30, 2024 | Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October | - |
| Aug 30, 2024 | Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February | - |
| Aug 30, 2024 | Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January | - |
| Aug 30, 2024 | Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October | - |
| Aug 30, 2024 | Exhibit Pm 2.2 Neutropenia Msd Manual | - |
| Aug 30, 2024 | Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana | - |
| Aug 30, 2024 | Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July | - |
| Aug 30, 2024 | Exhibit Pm 1.2 Extract Sanofi Annual Reports | - |
| Aug 30, 2024 | Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip | - |
| Aug 30, 2024 | Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August | - |
| Aug 30, 2024 | 44999 Proof Of Court Fees Payment | - |
| Oct 11, 2025 | Final Order | |
| Oct 11, 2025 | Action.Phasechange | - |
| Oct 11, 2025 | Action.Issuedecision | - |
| Oct 10, 2025 | Signature Image | - |
| Oct 10, 2025 | Receipt | - |
| Oct 10, 2025 | Other Document | - |
| Oct 10, 2025 | Cover Sheet | - |
| Oct 10, 2025 | Application | - |
| Oct 8, 2025 | Receipt | - |
| Oct 8, 2025 | Further Pleadings | - |
| Oct 8, 2025 | Exhibit | - |
| Oct 8, 2025 | Cover Sheet | - |
| Sep 15, 2025 | Oral Hearing Reference Ic | - |
| Sep 10, 2025 | Written Procedure Closure | - |
| Sep 10, 2025 | Interim Conference Decision | - |
| Sep 10, 2025 | Fix Interim Conference Date | - |
| Aug 8, 2025 | Rejoinder | - |
| Aug 8, 2025 | Exhibit No. B.22 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. 0 | - |
| Aug 8, 2025 | Acknowledgement Of Lodging | - |
| Jul 16, 2025 | Outcome Of The Order | - |
| Jul 16, 2025 | 262 A Final (Again For The Old) | |
| Jul 16, 2025 | 262 A Final | |
| Jul 11, 2025 | Acknowledgement Of Change Of A Representative | - |
| Jul 9, 2025 | Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version | - |
| Jul 9, 2025 | Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February | - |
| Jul 9, 2025 | Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January | - |
| Jul 9, 2025 | Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January | - |
| Jul 9, 2025 | Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January | - |
| Jul 9, 2025 | Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January | - |
| Jul 9, 2025 | Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December | - |
| Jul 9, 2025 | Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November | - |
| Jul 9, 2025 | Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October | - |
| Jul 9, 2025 | Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April | - |
| Jul 9, 2025 | Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives | - |
| Jul 9, 2025 | Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February . | - |
| Jul 9, 2025 | Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November | - |
| Jul 9, 2025 | Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October | - |
| Jul 9, 2025 | Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July | - |
| Jul 9, 2025 | Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June | - |
| Jul 9, 2025 | Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published | - |
| Jul 9, 2025 | Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed) | - |
| Jul 9, 2025 | Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period | - |
| Jul 9, 2025 | Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416 | - |
| Jul 9, 2025 | Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version) | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202 | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July . | - |
| Jul 9, 2025 | Act 16112 And Accord Application 262A Rop 8 July | - |
| Jul 9, 2025 | Acknowledgement Of Lodging | - |
| Jul 8, 2025 | Formal Checks Notification Of Positive Outcome | - |
| Jul 8, 2025 | Application Rop293 Receipt | - |
| Jun 27, 2025 | Application Rop293 | - |
| Jun 27, 2025 | Application | - |
| May 23, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 22, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 22, 2025 | Application Rop293 Receipt | - |
| May 22, 2025 | Application Rop293 | - |
| May 22, 2025 | Application Change Of Representative Jules Fabre Signed | - |
| May 22, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 21, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 21, 2025 | Application Rop293 Receipt | - |
| May 19, 2025 | Application Rop293 | - |
| May 19, 2025 | Application Change Of Representative | - |
| Jan 24, 2025 | Scheduling Ic And Oh For Cc | |
| Jan 24, 2025 | Hearing Dates | - |
| Jan 17, 2025 | R 305 Second Final | |
| Jan 17, 2025 | Outcome Of The Order | - |
| Jan 16, 2025 | Hearing Reference | - |
| Jan 13, 2025 | R 305 Second Oral Comments | - |
| Jan 13, 2025 | Hearing Dates | - |
| Jan 9, 2025 | Receipt | - |
| Jan 9, 2025 | Exhibit No. A.02 | - |
| Jan 9, 2025 | Application | - |
| Dec 19, 2024 | Outcome Of The Order | - |
| Dec 19, 2024 | Extension Request | |
| Dec 10, 2024 | Receipt | - |
| Dec 9, 2024 | 12 09 Accord Request For Extension Of Deadline | - |
| Dec 5, 2024 | Acknowledgement Of Lodging | - |
| Dec 5, 2024 | 12 05 Application To Change Details Of A Representative 64597 | - |
| Nov 1, 2024 | Reply And Defence | - |
| Nov 1, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Nov 1, 2024 | Acknowledgement Of Lodging | - |
| Sep 17, 2024 | Epouploaddocumentsworkflow | - |
| Sep 16, 2024 | Document From Epo | - |
| Sep 6, 2024 | Panel Appointment | - |
| Sep 6, 2024 | Notification Of Service | - |
| Sep 6, 2024 | Epo Request For Case Pending | - |
| Sep 6, 2024 | Acknowledgement Of Lodging | - |
| Sep 6, 2024 | Acknowledgement Of Access To Case | - |
| Sep 4, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Aug 30, 2024 | Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec | - |
| Aug 30, 2024 | Exhibit Pm 6.2 Order 7 June First Instance Court | - |
| Aug 30, 2024 | Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July | - |
| Aug 30, 2024 | Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998 | - |
| Aug 30, 2024 | Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun. | - |
| Aug 30, 2024 | Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere | - |
| Aug 30, 2024 | Exhibit Pm 5.5 Us 065138 A1 | - |
| Aug 30, 2024 | Exhibit Pm 5.4 Declaration By Prof. Stefan Muller | - |
| Aug 30, 2024 | Exhibit Pm 5.3 Declaration By Dr. Kurt Miller | - |
| Aug 30, 2024 | Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us | - |
| Aug 30, 2024 | Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.33 Extracts From Sanofi Annual Report | - |
| Aug 30, 2024 | Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June | - |
| Aug 30, 2024 | Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging | - |
| Aug 30, 2024 | Exhibit Pm 5.30 Screenshot From Openpaymentsdata. | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1) | - |
| Aug 30, 2024 | Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings | - |
| Aug 30, 2024 | Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April | - |
| Aug 30, 2024 | Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December | - |
| Aug 30, 2024 | Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono | - |
| Aug 30, 2024 | Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet | - |
| Aug 30, 2024 | Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May | - |
| Aug 30, 2024 | Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And | - |
| Aug 30, 2024 | Exhibit Pm 5.22 Sanofi Press Release DATED 21 December | - |
| Aug 30, 2024 | Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade | - |
| Aug 30, 2024 | Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study | - |
| Aug 30, 2024 | Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May | - |
| Aug 30, 2024 | Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda | - |
| Aug 30, 2024 | Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October | - |
| Aug 30, 2024 | Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics | - |
| Aug 30, 2024 | Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December | - |
| Aug 30, 2024 | Exhibit Pm 4.9 Further Observations Accord Of 10 December | - |
| Aug 30, 2024 | Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March | - |
| Aug 30, 2024 | Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo | - |
| Aug 30, 2024 | Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation | - |
| Aug 30, 2024 | Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August | - |
| Aug 30, 2024 | Exhibit Pm 4.4 Priority Document No. US61293903(P2) | - |
| Aug 30, 2024 | Exhibit Pm 4.3 Priority Document No. US61256160(P1) | - |
| Aug 30, 2024 | Exhibit Pm 4.2 Wo 051894 A1 | - |
| Aug 30, 2024 | Exhibit Pm 4.1 Ep E 493 466 B1 | - |
| Aug 30, 2024 | Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas | - |
| Aug 30, 2024 | Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October | - |
| Aug 30, 2024 | Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May | - |
| Aug 30, 2024 | Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January | - |
| Aug 30, 2024 | Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January | - |
| Aug 30, 2024 | Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord | - |
| Aug 30, 2024 | Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data) | - |
| Aug 30, 2024 | Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October | - |
| Aug 30, 2024 | Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October | - |
| Aug 30, 2024 | Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February | - |
| Aug 30, 2024 | Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January | - |
| Aug 30, 2024 | Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October | - |
| Aug 30, 2024 | Exhibit Pm 2.2 Neutropenia Msd Manual | - |
| Aug 30, 2024 | Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana | - |
| Aug 30, 2024 | Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July | - |
| Aug 30, 2024 | Exhibit Pm 1.2 Extract Sanofi Annual Reports | - |
| Aug 30, 2024 | Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip | - |
| Aug 30, 2024 | Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August | - |
| Aug 30, 2024 | 44999 Proof Of Court Fees Payment | - |
| Oct 11, 2025 | Final Order | |
| Oct 11, 2025 | Action.Phasechange | - |
| Oct 11, 2025 | Action.Issuedecision | - |
| Oct 10, 2025 | Signature Image | - |
| Oct 10, 2025 | Receipt | - |
| Oct 10, 2025 | Other Document | - |
| Oct 10, 2025 | Cover Sheet | - |
| Oct 10, 2025 | Application | - |
| Oct 8, 2025 | Receipt | - |
| Oct 8, 2025 | Further Pleadings | - |
| Oct 8, 2025 | Exhibit | - |
| Oct 8, 2025 | Cover Sheet | - |
| Sep 15, 2025 | Oral Hearing Reference Ic | - |
| Sep 10, 2025 | Written Procedure Closure | - |
| Sep 10, 2025 | Interim Conference Decision | - |
| Sep 10, 2025 | Fix Interim Conference Date | - |
| Aug 8, 2025 | Rejoinder | - |
| Aug 8, 2025 | Exhibit No. B.22 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. 0 | - |
| Aug 8, 2025 | Acknowledgement Of Lodging | - |
| Jul 16, 2025 | Outcome Of The Order | - |
| Jul 16, 2025 | 262 A Final (Again For The Old) | |
| Jul 16, 2025 | 262 A Final | |
| Jul 11, 2025 | Acknowledgement Of Change Of A Representative | - |
| Jul 9, 2025 | Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version | - |
| Jul 9, 2025 | Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February | - |
| Jul 9, 2025 | Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January | - |
| Jul 9, 2025 | Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January | - |
| Jul 9, 2025 | Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January | - |
| Jul 9, 2025 | Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January | - |
| Jul 9, 2025 | Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December | - |
| Jul 9, 2025 | Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November | - |
| Jul 9, 2025 | Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October | - |
| Jul 9, 2025 | Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April | - |
| Jul 9, 2025 | Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives | - |
| Jul 9, 2025 | Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February . | - |
| Jul 9, 2025 | Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November | - |
| Jul 9, 2025 | Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October | - |
| Jul 9, 2025 | Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July | - |
| Jul 9, 2025 | Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June | - |
| Jul 9, 2025 | Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published | - |
| Jul 9, 2025 | Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed) | - |
| Jul 9, 2025 | Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period | - |
| Jul 9, 2025 | Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416 | - |
| Jul 9, 2025 | Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version) | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202 | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July . | - |
| Jul 9, 2025 | Act 16112 And Accord Application 262A Rop 8 July | - |
| Jul 9, 2025 | Acknowledgement Of Lodging | - |
| Jul 8, 2025 | Formal Checks Notification Of Positive Outcome | - |
| Jul 8, 2025 | Application Rop293 Receipt | - |
| Jun 27, 2025 | Application Rop293 | - |
| Jun 27, 2025 | Application | - |
| May 23, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 22, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 22, 2025 | Application Rop293 Receipt | - |
| May 22, 2025 | Application Rop293 | - |
| May 22, 2025 | Application Change Of Representative Jules Fabre Signed | - |
| May 22, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 21, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 21, 2025 | Application Rop293 Receipt | - |
| May 19, 2025 | Application Rop293 | - |
| May 19, 2025 | Application Change Of Representative | - |
| Jan 24, 2025 | Scheduling Ic And Oh For Cc | |
| Jan 24, 2025 | Hearing Dates | - |
| Jan 17, 2025 | R 305 Second Final | |
| Jan 17, 2025 | Outcome Of The Order | - |
| Jan 16, 2025 | Hearing Reference | - |
| Jan 13, 2025 | R 305 Second Oral Comments | - |
| Jan 13, 2025 | Hearing Dates | - |
| Jan 9, 2025 | Receipt | - |
| Jan 9, 2025 | Exhibit No. A.02 | - |
| Jan 9, 2025 | Application | - |
| Dec 19, 2024 | Outcome Of The Order | - |
| Dec 19, 2024 | Extension Request | |
| Dec 10, 2024 | Receipt | - |
| Dec 9, 2024 | 12 09 Accord Request For Extension Of Deadline | - |
| Dec 5, 2024 | Acknowledgement Of Lodging | - |
| Dec 5, 2024 | 12 05 Application To Change Details Of A Representative 64597 | - |
| Nov 1, 2024 | Reply And Defence | - |
| Nov 1, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Nov 1, 2024 | Acknowledgement Of Lodging | - |
| Sep 17, 2024 | Epouploaddocumentsworkflow | - |
| Sep 16, 2024 | Document From Epo | - |
| Sep 6, 2024 | Panel Appointment | - |
| Sep 6, 2024 | Notification Of Service | - |
| Sep 6, 2024 | Epo Request For Case Pending | - |
| Sep 6, 2024 | Acknowledgement Of Lodging | - |
| Sep 6, 2024 | Acknowledgement Of Access To Case | - |
| Sep 4, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Aug 30, 2024 | Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec | - |
| Aug 30, 2024 | Exhibit Pm 6.2 Order 7 June First Instance Court | - |
| Aug 30, 2024 | Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July | - |
| Aug 30, 2024 | Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998 | - |
| Aug 30, 2024 | Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun. | - |
| Aug 30, 2024 | Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere | - |
| Aug 30, 2024 | Exhibit Pm 5.5 Us 065138 A1 | - |
| Aug 30, 2024 | Exhibit Pm 5.4 Declaration By Prof. Stefan Muller | - |
| Aug 30, 2024 | Exhibit Pm 5.3 Declaration By Dr. Kurt Miller | - |
| Aug 30, 2024 | Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us | - |
| Aug 30, 2024 | Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.33 Extracts From Sanofi Annual Report | - |
| Aug 30, 2024 | Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June | - |
| Aug 30, 2024 | Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging | - |
| Aug 30, 2024 | Exhibit Pm 5.30 Screenshot From Openpaymentsdata. | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1) | - |
| Aug 30, 2024 | Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings | - |
| Aug 30, 2024 | Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April | - |
| Aug 30, 2024 | Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December | - |
| Aug 30, 2024 | Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono | - |
| Aug 30, 2024 | Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet | - |
| Aug 30, 2024 | Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May | - |
| Aug 30, 2024 | Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And | - |
| Aug 30, 2024 | Exhibit Pm 5.22 Sanofi Press Release DATED 21 December | - |
| Aug 30, 2024 | Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade | - |
| Aug 30, 2024 | Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study | - |
| Aug 30, 2024 | Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May | - |
| Aug 30, 2024 | Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda | - |
| Aug 30, 2024 | Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October | - |
| Aug 30, 2024 | Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics | - |
| Aug 30, 2024 | Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December | - |
| Aug 30, 2024 | Exhibit Pm 4.9 Further Observations Accord Of 10 December | - |
| Aug 30, 2024 | Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March | - |
| Aug 30, 2024 | Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo | - |
| Aug 30, 2024 | Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation | - |
| Aug 30, 2024 | Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August | - |
| Aug 30, 2024 | Exhibit Pm 4.4 Priority Document No. US61293903(P2) | - |
| Aug 30, 2024 | Exhibit Pm 4.3 Priority Document No. US61256160(P1) | - |
| Aug 30, 2024 | Exhibit Pm 4.2 Wo 051894 A1 | - |
| Aug 30, 2024 | Exhibit Pm 4.1 Ep E 493 466 B1 | - |
| Aug 30, 2024 | Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas | - |
| Aug 30, 2024 | Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October | - |
| Aug 30, 2024 | Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May | - |
| Aug 30, 2024 | Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January | - |
| Aug 30, 2024 | Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January | - |
| Aug 30, 2024 | Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord | - |
| Aug 30, 2024 | Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data) | - |
| Aug 30, 2024 | Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October | - |
| Aug 30, 2024 | Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October | - |
| Aug 30, 2024 | Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February | - |
| Aug 30, 2024 | Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January | - |
| Aug 30, 2024 | Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October | - |
| Aug 30, 2024 | Exhibit Pm 2.2 Neutropenia Msd Manual | - |
| Aug 30, 2024 | Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana | - |
| Aug 30, 2024 | Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July | - |
| Aug 30, 2024 | Exhibit Pm 1.2 Extract Sanofi Annual Reports | - |
| Aug 30, 2024 | Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip | - |
| Aug 30, 2024 | Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August | - |
| Aug 30, 2024 | 44999 Proof Of Court Fees Payment | - |
| Oct 11, 2025 | Final Order | |
| Oct 11, 2025 | Action.Phasechange | - |
| Oct 11, 2025 | Action.Issuedecision | - |
| Oct 10, 2025 | Signature Image | - |
| Oct 10, 2025 | Receipt | - |
| Oct 10, 2025 | Other Document | - |
| Oct 10, 2025 | Cover Sheet | - |
| Oct 10, 2025 | Application | - |
| Oct 8, 2025 | Receipt | - |
| Oct 8, 2025 | Further Pleadings | - |
| Oct 8, 2025 | Exhibit | - |
| Oct 8, 2025 | Cover Sheet | - |
| Sep 15, 2025 | Oral Hearing Reference Ic | - |
| Sep 10, 2025 | Written Procedure Closure | - |
| Sep 10, 2025 | Interim Conference Decision | - |
| Sep 10, 2025 | Fix Interim Conference Date | - |
| Aug 8, 2025 | Rejoinder | - |
| Aug 8, 2025 | Exhibit No. B.22 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. 0 | - |
| Aug 8, 2025 | Acknowledgement Of Lodging | - |
| Jul 16, 2025 | Outcome Of The Order | - |
| Jul 16, 2025 | 262 A Final (Again For The Old) | |
| Jul 16, 2025 | 262 A Final | |
| Jul 11, 2025 | Acknowledgement Of Change Of A Representative | - |
| Jul 9, 2025 | Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version | - |
| Jul 9, 2025 | Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February | - |
| Jul 9, 2025 | Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January | - |
| Jul 9, 2025 | Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January | - |
| Jul 9, 2025 | Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January | - |
| Jul 9, 2025 | Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January | - |
| Jul 9, 2025 | Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December | - |
| Jul 9, 2025 | Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November | - |
| Jul 9, 2025 | Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October | - |
| Jul 9, 2025 | Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April | - |
| Jul 9, 2025 | Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives | - |
| Jul 9, 2025 | Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February . | - |
| Jul 9, 2025 | Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November | - |
| Jul 9, 2025 | Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October | - |
| Jul 9, 2025 | Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July | - |
| Jul 9, 2025 | Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June | - |
| Jul 9, 2025 | Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published | - |
| Jul 9, 2025 | Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed) | - |
| Jul 9, 2025 | Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period | - |
| Jul 9, 2025 | Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416 | - |
| Jul 9, 2025 | Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version) | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202 | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July . | - |
| Jul 9, 2025 | Act 16112 And Accord Application 262A Rop 8 July | - |
| Jul 9, 2025 | Acknowledgement Of Lodging | - |
| Jul 8, 2025 | Formal Checks Notification Of Positive Outcome | - |
| Jul 8, 2025 | Application Rop293 Receipt | - |
| Jun 27, 2025 | Application Rop293 | - |
| Jun 27, 2025 | Application | - |
| May 23, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 22, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 22, 2025 | Application Rop293 Receipt | - |
| May 22, 2025 | Application Rop293 | - |
| May 22, 2025 | Application Change Of Representative Jules Fabre Signed | - |
| May 22, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 21, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 21, 2025 | Application Rop293 Receipt | - |
| May 19, 2025 | Application Rop293 | - |
| May 19, 2025 | Application Change Of Representative | - |
| Jan 24, 2025 | Scheduling Ic And Oh For Cc | |
| Jan 24, 2025 | Hearing Dates | - |
| Jan 17, 2025 | R 305 Second Final | |
| Jan 17, 2025 | Outcome Of The Order | - |
| Jan 16, 2025 | Hearing Reference | - |
| Jan 13, 2025 | R 305 Second Oral Comments | - |
| Jan 13, 2025 | Hearing Dates | - |
| Jan 9, 2025 | Receipt | - |
| Jan 9, 2025 | Exhibit No. A.02 | - |
| Jan 9, 2025 | Application | - |
| Dec 19, 2024 | Outcome Of The Order | - |
| Dec 19, 2024 | Extension Request | |
| Dec 10, 2024 | Receipt | - |
| Dec 9, 2024 | 12 09 Accord Request For Extension Of Deadline | - |
| Dec 5, 2024 | Acknowledgement Of Lodging | - |
| Dec 5, 2024 | 12 05 Application To Change Details Of A Representative 64597 | - |
| Nov 1, 2024 | Reply And Defence | - |
| Nov 1, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Nov 1, 2024 | Acknowledgement Of Lodging | - |
| Sep 17, 2024 | Epouploaddocumentsworkflow | - |
| Sep 16, 2024 | Document From Epo | - |
| Sep 6, 2024 | Panel Appointment | - |
| Sep 6, 2024 | Notification Of Service | - |
| Sep 6, 2024 | Epo Request For Case Pending | - |
| Sep 6, 2024 | Acknowledgement Of Lodging | - |
| Sep 6, 2024 | Acknowledgement Of Access To Case | - |
| Sep 4, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Aug 30, 2024 | Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec | - |
| Aug 30, 2024 | Exhibit Pm 6.2 Order 7 June First Instance Court | - |
| Aug 30, 2024 | Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July | - |
| Aug 30, 2024 | Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998 | - |
| Aug 30, 2024 | Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun. | - |
| Aug 30, 2024 | Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere | - |
| Aug 30, 2024 | Exhibit Pm 5.5 Us 065138 A1 | - |
| Aug 30, 2024 | Exhibit Pm 5.4 Declaration By Prof. Stefan Muller | - |
| Aug 30, 2024 | Exhibit Pm 5.3 Declaration By Dr. Kurt Miller | - |
| Aug 30, 2024 | Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us | - |
| Aug 30, 2024 | Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.33 Extracts From Sanofi Annual Report | - |
| Aug 30, 2024 | Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June | - |
| Aug 30, 2024 | Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging | - |
| Aug 30, 2024 | Exhibit Pm 5.30 Screenshot From Openpaymentsdata. | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1) | - |
| Aug 30, 2024 | Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings | - |
| Aug 30, 2024 | Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April | - |
| Aug 30, 2024 | Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December | - |
| Aug 30, 2024 | Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono | - |
| Aug 30, 2024 | Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet | - |
| Aug 30, 2024 | Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May | - |
| Aug 30, 2024 | Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And | - |
| Aug 30, 2024 | Exhibit Pm 5.22 Sanofi Press Release DATED 21 December | - |
| Aug 30, 2024 | Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade | - |
| Aug 30, 2024 | Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study | - |
| Aug 30, 2024 | Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May | - |
| Aug 30, 2024 | Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda | - |
| Aug 30, 2024 | Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October | - |
| Aug 30, 2024 | Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics | - |
| Aug 30, 2024 | Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December | - |
| Aug 30, 2024 | Exhibit Pm 4.9 Further Observations Accord Of 10 December | - |
| Aug 30, 2024 | Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March | - |
| Aug 30, 2024 | Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo | - |
| Aug 30, 2024 | Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation | - |
| Aug 30, 2024 | Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August | - |
| Aug 30, 2024 | Exhibit Pm 4.4 Priority Document No. US61293903(P2) | - |
| Aug 30, 2024 | Exhibit Pm 4.3 Priority Document No. US61256160(P1) | - |
| Aug 30, 2024 | Exhibit Pm 4.2 Wo 051894 A1 | - |
| Aug 30, 2024 | Exhibit Pm 4.1 Ep E 493 466 B1 | - |
| Aug 30, 2024 | Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas | - |
| Aug 30, 2024 | Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October | - |
| Aug 30, 2024 | Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May | - |
| Aug 30, 2024 | Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January | - |
| Aug 30, 2024 | Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January | - |
| Aug 30, 2024 | Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord | - |
| Aug 30, 2024 | Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data) | - |
| Aug 30, 2024 | Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October | - |
| Aug 30, 2024 | Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October | - |
| Aug 30, 2024 | Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February | - |
| Aug 30, 2024 | Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January | - |
| Aug 30, 2024 | Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October | - |
| Aug 30, 2024 | Exhibit Pm 2.2 Neutropenia Msd Manual | - |
| Aug 30, 2024 | Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana | - |
| Aug 30, 2024 | Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July | - |
| Aug 30, 2024 | Exhibit Pm 1.2 Extract Sanofi Annual Reports | - |
| Aug 30, 2024 | Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip | - |
| Aug 30, 2024 | Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August | - |
| Aug 30, 2024 | 44999 Proof Of Court Fees Payment | - |
| Oct 11, 2025 | Final Order | |
| Oct 11, 2025 | Action.Phasechange | - |
| Oct 11, 2025 | Action.Issuedecision | - |
| Oct 10, 2025 | Signature Image | - |
| Oct 10, 2025 | Receipt | - |
| Oct 10, 2025 | Other Document | - |
| Oct 10, 2025 | Cover Sheet | - |
| Oct 10, 2025 | Application | - |
| Oct 8, 2025 | Receipt | - |
| Oct 8, 2025 | Further Pleadings | - |
| Oct 8, 2025 | Exhibit | - |
| Oct 8, 2025 | Cover Sheet | - |
| Sep 15, 2025 | Oral Hearing Reference Ic | - |
| Sep 10, 2025 | Written Procedure Closure | - |
| Sep 10, 2025 | Interim Conference Decision | - |
| Sep 10, 2025 | Fix Interim Conference Date | - |
| Aug 8, 2025 | Rejoinder | - |
| Aug 8, 2025 | Exhibit No. B.22 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B.2.2 | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. B | - |
| Aug 8, 2025 | Exhibit No. 0 | - |
| Aug 8, 2025 | Acknowledgement Of Lodging | - |
| Jul 16, 2025 | Outcome Of The Order | - |
| Jul 16, 2025 | 262 A Final (Again For The Old) | |
| Jul 16, 2025 | 262 A Final | |
| Jul 11, 2025 | Acknowledgement Of Change Of A Representative | - |
| Jul 9, 2025 | Exhibit Tw 8.9 Upc Cfi 145 (Ld Munich) Order Of 8 May Redacted Version | - |
| Jul 9, 2025 | Exhibit Tw 8.8 Upc Cfi 145 (Ld Munich) Order Of 27 February | - |
| Jul 9, 2025 | Exhibit Tw 8.7 Upc Cfi 145 (Ld Munich) Order Of 22 January | - |
| Jul 9, 2025 | Exhibit Tw 8.6 Upc Cfi 145 (Ld Munich) Order Of 14 January | - |
| Jul 9, 2025 | Exhibit Tw 8.5 Upc Cfi 145 (Ld Munich) Order Of 9 January | - |
| Jul 9, 2025 | Exhibit Tw 8.4 Upc Cfi 145 (Ld Munich) Order Of 3 January | - |
| Jul 9, 2025 | Exhibit Tw 8.3 Upc Cfi 145 (Ld Munich) Order Of 19 December | - |
| Jul 9, 2025 | Exhibit Tw 8.2 Upc Cfi 145 (Ld Munich) Order Of 5 November | - |
| Jul 9, 2025 | Exhibit Tw 8.1 Upc Cfi 145 (Ld Munich) Orders Of 1St October | - |
| Jul 9, 2025 | Exhibit Tw 8.16 Accord S Comments On Sanofi S Further Amended Requests Filed 9 April | - |
| Jul 9, 2025 | Exhibit Tw 8.15 Official Communication 3 March From Accord Upc Representatives To Sanofi Upc Representatives | - |
| Jul 9, 2025 | Exhibit Tw 8.14 Accord Comments On Sanofi Amended Requests And Rejoinder To Sanofi Comments Filed On 12 February . | - |
| Jul 9, 2025 | Exhibit Tw 8.13 Accord Comments On 262A Sanofi S Request Filed On 12 November | - |
| Jul 9, 2025 | Exhibit Tw 8.12 Accord S Rejoinder To The Sanofi S Comments On The Preliminary Objections Filed 11 October | - |
| Jul 9, 2025 | Exhibit Tw 8.11 Accord S Preliminary Objections And Generic Procedural Application Filed 1 July | - |
| Jul 9, 2025 | Exhibit Tw 8.10 Upc Cfi 148 (Ld Munich) Order Of 27 June | - |
| Jul 9, 2025 | Exhibit Tw 7.2 Extracts W Tilmann And C Plasmann Unified Patent Protection In Europe A Commentary Book 1St Ed Published | - |
| Jul 9, 2025 | Exhibit Tw 6.5 Schedule Of Costs For The Defendants As Of 8 July (Signed) | - |
| Jul 9, 2025 | Exhibit Tw 6.4 Sanofi Winthrop Industries Annuals Report For The Period | - |
| Jul 9, 2025 | Exhibit Tw 6.3 Paris Court Judgment Issued On 6 September Accord V Sanofi Rg 21 06416 | - |
| Jul 9, 2025 | Exhibit Tw 5.35Bis Sanofi Annual Report 20 F In The Us (Complete Version) | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Unredacted Version 8 July 202 | - |
| Jul 9, 2025 | Act 16112 And Accord Reply To The Defence To The Counterclaim And Rejoinder Redacted Version 8 July . | - |
| Jul 9, 2025 | Act 16112 And Accord Application 262A Rop 8 July | - |
| Jul 9, 2025 | Acknowledgement Of Lodging | - |
| Jul 8, 2025 | Formal Checks Notification Of Positive Outcome | - |
| Jul 8, 2025 | Application Rop293 Receipt | - |
| Jun 27, 2025 | Application Rop293 | - |
| Jun 27, 2025 | Application | - |
| May 23, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 22, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 22, 2025 | Application Rop293 Receipt | - |
| May 22, 2025 | Application Rop293 | - |
| May 22, 2025 | Application Change Of Representative Jules Fabre Signed | - |
| May 22, 2025 | Acknowledgement Of Change Of A Representative | - |
| May 21, 2025 | Formal Checks Notification Of Positive Outcome | - |
| May 21, 2025 | Application Rop293 Receipt | - |
| May 19, 2025 | Application Rop293 | - |
| May 19, 2025 | Application Change Of Representative | - |
| Jan 24, 2025 | Scheduling Ic And Oh For Cc | |
| Jan 24, 2025 | Hearing Dates | - |
| Jan 17, 2025 | R 305 Second Final | |
| Jan 17, 2025 | Outcome Of The Order | - |
| Jan 16, 2025 | Hearing Reference | - |
| Jan 13, 2025 | R 305 Second Oral Comments | - |
| Jan 13, 2025 | Hearing Dates | - |
| Jan 9, 2025 | Receipt | - |
| Jan 9, 2025 | Exhibit No. A.02 | - |
| Jan 9, 2025 | Application | - |
| Dec 19, 2024 | Outcome Of The Order | - |
| Dec 19, 2024 | Extension Request | |
| Dec 10, 2024 | Receipt | - |
| Dec 9, 2024 | 12 09 Accord Request For Extension Of Deadline | - |
| Dec 5, 2024 | Acknowledgement Of Lodging | - |
| Dec 5, 2024 | 12 05 Application To Change Details Of A Representative 64597 | - |
| Nov 1, 2024 | Reply And Defence | - |
| Nov 1, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Nov 1, 2024 | Acknowledgement Of Lodging | - |
| Sep 17, 2024 | Epouploaddocumentsworkflow | - |
| Sep 16, 2024 | Document From Epo | - |
| Sep 6, 2024 | Panel Appointment | - |
| Sep 6, 2024 | Notification Of Service | - |
| Sep 6, 2024 | Epo Request For Case Pending | - |
| Sep 6, 2024 | Acknowledgement Of Lodging | - |
| Sep 6, 2024 | Acknowledgement Of Access To Case | - |
| Sep 4, 2024 | Formal Checks Notification Of Positive Outcome | - |
| Aug 30, 2024 | Exhibit Pm 7.1 Extract Paul England A Practioners Guide To The Upc And Up Dec | - |
| Aug 30, 2024 | Exhibit Pm 6.2 Order 7 June First Instance Court | - |
| Aug 30, 2024 | Exhibit Pm 6.1 Excerpts Iqvia Audit Data Presentation July | - |
| Aug 30, 2024 | Exhibit Pm 5.9 Ich Topic E8 Note For Guidance On General Considerations For Clinical Trials March 1998 | - |
| Aug 30, 2024 | Exhibit Pm 5.8 Tannock Et Al. Chemotherapy With Mitoxantrone Plus Prednisone (...)1996 Jun. | - |
| Aug 30, 2024 | Exhibit Pm 5.7 Tannock Et Al. Docetaxel Plus Prednisone Or Mitoxantrone Plus Prednisone (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.6 Extracts From The Summary Of Product Characteristics Of Taxotere | - |
| Aug 30, 2024 | Exhibit Pm 5.5 Us 065138 A1 | - |
| Aug 30, 2024 | Exhibit Pm 5.4 Declaration By Prof. Stefan Muller | - |
| Aug 30, 2024 | Exhibit Pm 5.3 Declaration By Dr. Kurt Miller | - |
| Aug 30, 2024 | Exhibit Pm 5.36 Galletti Et Al. Paclitaxel And Docetaxel Resistance (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.35 Extracts Sanofi Annual Report 20 F In The Us | - |
| Aug 30, 2024 | Exhibit Pm 5.34 Fitzpatrick Et Al. Treatment Decisions For Advanced Genitourinary (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.33 Extracts From Sanofi Annual Report | - |
| Aug 30, 2024 | Exhibit Pm 5.32 Madan Et Al. Overcoming Chemotherapy Resistance In Prostate Cancer (...) June | - |
| Aug 30, 2024 | Exhibit Pm 5.31 Kumar Pal Et Al. CR Itical Appraisal Of Cabazitaxel (...) Clinical Interventions In Aging | - |
| Aug 30, 2024 | Exhibit Pm 5.30 Screenshot From Openpaymentsdata. | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 4) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr Samuel Denmaede (Part 3) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 2) | - |
| Aug 30, 2024 | Exhibit Pm 5.2 Annexes To The Declaration By Dr. Samuel Denmaede (Part 1) | - |
| Aug 30, 2024 | Exhibit Pm 5.29 Extracts From Dr. Sartor Deposition Transcript Of 8 May In The Us Proceedings | - |
| Aug 30, 2024 | Exhibit Pm 5.28 Declaration By Dr. Sartor Before The Patent And Trial And Appeal Board 20 April | - |
| Aug 30, 2024 | Exhibit Pm 5.27 Declaration By Dr. Sartor Of 23 December | - |
| Aug 30, 2024 | Exhibit Pm 5.26 Correspondence In The Lancet () Re Pm 5.25 Froehner And Wirth V. De Bono | - |
| Aug 30, 2024 | Exhibit Pm 5.25 De Bono Et Al. Prednisone Plus Cabazitaxel Or Mitoxantrone (...) The Lancet | - |
| Aug 30, 2024 | Exhibit Pm 5.24 Screenshot From Clinicaltrial.Gov Xrp6258 Plus Prednisone Compared To (...) 3 May | - |
| Aug 30, 2024 | Exhibit Pm 5.23 Wayback Machine Extracts From Clinicaltrial.Gov. And | - |
| Aug 30, 2024 | Exhibit Pm 5.22 Sanofi Press Release DATED 21 December | - |
| Aug 30, 2024 | Exhibit Pm 5.21 Tropic Trial Protocol In A Document Entitled Cabazitaxel (Xrp 6258) For Hormone (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.20 Beardsley Et Al. Systemic Therapy After First Line Docetaxel (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.1 Declaration By Dr. Samuel Denmeade | - |
| Aug 30, 2024 | Exhibit Pm 5.19 Pivot Et Al. A Multicenter Phase Ii Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.18 Mita Et Al. Phase I And Pharmacokinetic Study Of Xrp6258 (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.17 Berthold Et Al. Survival And Psa Response Of Patients In The Tax 327 Study | - |
| Aug 30, 2024 | Exhibit Pm 5.16 Oudard Et Al. Multicenter Randomized Phase Ii Study (...) May | - |
| Aug 30, 2024 | Exhibit Pm 5.15 Petrylak Et Al. Docetaxel And Estramustine Compared (...) Oct. | - |
| Aug 30, 2024 | Exhibit Pm 5.14 Label Novantrone (Mitoxantrone) Fda | - |
| Aug 30, 2024 | Exhibit Pm 5.13 Scher Et Al. Design And End Points Of Clinical Trials For Patients (...) | - |
| Aug 30, 2024 | Exhibit Pm 5.12 Declaration Of Helsinki Ethical Principles Of Medical Research Involving Human Subjects October | - |
| Aug 30, 2024 | Exhibit Pm 5.11 Wong And Siah Estimation Of Clinical Trial Success Rates And Related Parameters Biostatistics | - |
| Aug 30, 2024 | Exhibit Pm 5.10 Chmp Guideline On The Evaluation Of Anticancer Medicinal Products In Man December | - |
| Aug 30, 2024 | Exhibit Pm 4.9 Further Observations Accord Of 10 December | - |
| Aug 30, 2024 | Exhibit Pm 4.8 Notice Of Opposition Accord Of 10 March | - |
| Aug 30, 2024 | Exhibit Pm 4.7 Record Of The Assignment Of EP466During Its Examination Before The Epo | - |
| Aug 30, 2024 | Exhibit Pm 4.6 Summons To Oral Proceedings By The Board Of Appeal And Date Confirmation | - |
| Aug 30, 2024 | Exhibit Pm 4.5 Extracts From The European Patent Register For EP2493466As At 21 August | - |
| Aug 30, 2024 | Exhibit Pm 4.4 Priority Document No. US61293903(P2) | - |
| Aug 30, 2024 | Exhibit Pm 4.3 Priority Document No. US61256160(P1) | - |
| Aug 30, 2024 | Exhibit Pm 4.2 Wo 051894 A1 | - |
| Aug 30, 2024 | Exhibit Pm 4.1 Ep E 493 466 B1 | - |
| Aug 30, 2024 | Exhibit Pm 4.14 Ip.Appify Blog Of 12 January Caselaw Epo Reviews Of Epo Boa Decisions Of D.X. Thomas | - |
| Aug 30, 2024 | Exhibit Pm 4.13 Decision Of The United States Patent Office (Uspto) Of 22 October | - |
| Aug 30, 2024 | Exhibit Pm 4.12 Grounds Of Appeal Accord Of 24 May | - |
| Aug 30, 2024 | Exhibit Pm 4.11 Notice Of Appeal Accord Of 15 January | - |
| Aug 30, 2024 | Exhibit Pm 4.10 Opposition Division Reasoned Decision Dated On 25 January | - |
| Aug 30, 2024 | Exhibit Pm 3.1 Summary Of Product Characteristics Of Cabazitaxel Accord | - |
| Aug 30, 2024 | Exhibit Pm 2.8 Sales Of Jevtana In European Countries In (Based On Iqvia Data) | - |
| Aug 30, 2024 | Exhibit Pm 2.7 Revue Prescrire Cabazitaxel Jevtana Trop Toxique Pour Une Efficacite Trop Incertaine October | - |
| Aug 30, 2024 | Exhibit Pm 2.6 Opinion Of The Transparency Committee Of The French National Health Authority 17 October | - |
| Aug 30, 2024 | Exhibit Pm 2.5 Refusal Notice Issued By The Inesss In February | - |
| Aug 30, 2024 | Exhibit Pm 2.4 Le Monde Sanofi Londres Refuse De Rembourser Le Jevtana Of 13 January | - |
| Aug 30, 2024 | Exhibit Pm 2.3 Opinion Of The Transparency Committee Of The French National Health Authority Of 19 October | - |
| Aug 30, 2024 | Exhibit Pm 2.2 Neutropenia Msd Manual | - |
| Aug 30, 2024 | Exhibit Pm 2.1 Summary Of Product Characteristics Of Jevtana | - |
| Aug 30, 2024 | Exhibit Pm 1.3 Communication From The Paris Court Of First Instance DATED 5 July | - |
| Aug 30, 2024 | Exhibit Pm 1.2 Extract Sanofi Annual Reports | - |
| Aug 30, 2024 | Exhibit Pm 1.1 French Company Registry Extract For Sanofi Mature Ip | - |
| Aug 30, 2024 | Act 16112 And 4499 2024 Accord Statement Of Defence And Counterclaim For Revocation 30 August | - |
| Aug 30, 2024 | 44999 Proof Of Court Fees Payment | - |